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Abstract 
Tea, from the plant Camellia Sinensis, is after water, the most consumed drink 
in the world. Green tea, produced by steaming freshly harvested leaves to 
prevent fermentation, is high in polyphenols known as catechins or flavanols. 
The major flavanols found in green tea include (-) epigallocatechin-3-gallate 
(EGCG) and (-) epicatechin. Literature reports suggest that green tea fla va no Is 
have the potential to exert anti-obesity effects by modulating weight gain and 
other factors such as lipogenesis, ~ - o x i d a t i o n n and adipokine release. Key 
features of obesity and associated insulin resistance are adipokine 
dysregulation, decreased sensitivity of adipocytes to insulin and subsequently, 
changes in glucose uptake by cells. 
The aims of this thesis were fIrstly to establish an .effIcient system of 
differentiated adipocytes and secondly to use this to investigate the effects of 
the flavanols EGCG and epicatechin on physiological outcomes such as 
adipokine release and glucose uptake. Thirdly, the question of whether these 
processes might be regulated by the ERK1I2 pathway and what may be 
happening upstream of this was explored. Finally, the effect of flavanol 
treatment on adipocyte gene expression of genes known to be modulated in 
obesity was investigated. 
Using the well established cell culture model of 3T3-LI adipocytes, the studies 
from this thesis show that EGCG and epicatechin are able to modulate the 
release of the adipokines adiponectin and resistin, dependent on the media 
glucose concentration. This modulation may be mediated by the ERK1I2 
pathway, since flavanol treatment increased ERKl/2 phosphorylation. Uptake 
of glucose was not altered by any time or concentration of EGCG or 
epicatechin, and there were no signifIcant changes in adipocyte gene 
expression following EGCG or epicatechin treatment. 
A thorough investigation of adipokine release, ERK signalling, glucose uptake 
and gene expression, under the influence of flavanol treatment, showed that 
although molecular changes occurred in the 3T3-Ll system, these did not 
translate into functional readouts. Therefore, it appears unlikely that these 
have major direct effects on adipocyte function. 
11 
Publications and Presentations: 
Mehra Anisha, Macdonald Ian (2007) Int JObes 31:S46-77 - Presented as a 
poster at European Congress on Obesity (Budapest 2007) 
Mehra A, Macdonald IA and Pillay TS (2007). "Variability m 3T3-L1 
adipocyte differentiation depending on cell culture dish." Anal Biochem 
362(2): 281-3. 
III 
Acknowledgements 
Firstly, I would like to thank my supervisors Prof Ian Macdonald and Dr 
Andrew Bennett. I am grateful for the opportunity that they gave me and for 
their guidance and support throughout. I also gratefully acknowledge the 
funding contributions from the BBRSC. 
Thank you to Profs Steve Alexander and Dave Kendall for help and advice on 
radioimmunoassays. Special thanks to everyone in the FRAME lab, especially 
Elke Gottshalg, Monika Owen, Nicola Bourne, Roya Babaei-ladidi and Deb 
Briggs for their invaluable help, advice and support. 
I would like to express my gratitude to all of the friends that I have made 
during my PhD, without whom I would have been lost. Namely Sarah, 
Veronica, Gillian, Amanda, Dave, Kirsten, Annie, Elke and Marleen. 
Particular thanks also to Cath, Sham and Luke. Thank you all for supporting 
me through the tough times and being there to celebrate the good times. 
Finally, heartfelt thanks to my family. Rohan for unfailing optimism, 
inspiration and enthusiasm and Papa for continued faith in me and an endless 
supply of good advice. Last but not least, Mum, who is always with me, and 
without whom I would not have come this far. 
---- -- - - - - - - - - - - ~ ~ ~ ~ ~ - ~ ~ ~ - - -
tv 
Contents 
1 Introduction ................................................................ 2 
1.1 ADIPOSE TISSUE ................................................................................................... 2 
1.1.1 Adipose Tissue Development ........................................................................... 3 
1.1.2 Regulation of Adipogenesis ............................................................................. 6 
1.2 ADIPOKINES ......................................................................................................... 9 
1.2.1 Adiponectin ................................................................ ................................... 10 
1.2.2 Resistin ............................................................. ............................................ 12 
1.3 ADIPOKINE REGULATION .................................................................................... 14 
1.3.1 Regulation of Adiponectin ............................................................................. 15 
1.3.2 Regulation ofResistin. ............................................................. ...................... 16 
1.4 ROLE OF MAPK ................................................................................................. 18 
1.4.1 The ERK112 MAPK Pathway ...................................................... ................... 19 
1.5 GREEN TEA CATECHINS ...................................................................................... 21 
1.5.1 Nomenclature ................................................. ............................................... 23 
1.5.2 Flavanol Content of Green Tea and Bioavailability ....................................... 25 
1.5.3 Flavanol Metabolism ................................................ ..................................... 25 
1.5.4 Interactions with ERK1I2 Pathway ................................................................ 27 
1.5.5 Anti-Obesity Effects (in vivo studies} .............................................................. 29 
1.5.6 Anti-Obesity Effects (in vitro studies} ............................................................. 32 
1.6 GLUCOSE UPTAKE .............................................................................................. 35 
1.7 SUMMARy .......................................................................................................... 38 
2 Materials & Methods ............................................... 40 
2.1 3T3-L1 CELL CULTURE ...................................................................................... 40 
2.1.1 Materials ................................................................. ..................................... 40 
2.1.2 Solutions ............................................................ ........................................... 41 
2.1.3 Cell Culture .................................................................................................. 41 
2.1.4 Oil Red 0 Staining ................................ ........................................................ 43 
2.2 . ELISA ............................................................................................................... 43 
2.2.1 Materials ................................................................................... ................... 43 
2.2.2 Method ................................................................ .......................................... 43 
2.3 WESTERN BLOTTING .......................................................................................... 44 
2.3.1 Materials ................................ ...................................................................... 44 
2.3.2 Solutions ............................................................................... ........................ 45 
2.3.3 Sample Preparation Using Phosphate Protective Lysis Buffer ........................ 46 
2.3.4 Sample Preparation Using TriReagent .......................................................... 47 
2.3.5 Protein Determination .............................................. ..................................... 48 
2.3.6 Electrophoresis ........................................................................ ..................... 49 
2.3.7 Blotting ................................ .................................................................... ..... 50 
2.3.8 Determination of Density of Protein Bands .................................................... 52 
2.3.9 Statistical Analysis ........................................................................................ 52 
2.4 GTPrS BINDING ASSAY ..................................................................................... 52 
2.4.1 Materials ...................................................................................................... 53 
2.4.2 Solutions ................................................. ...................................................... 53 
2.4.3 Method ........................................................ .................................................. 53 
2.5 2-DEOXYGLUCOSE UPTAKE ASSAY ..................................................................... 54 
2.5.1 Materials ...................................................................................................... 54 
2.5.2 Solutions .......................................................................... ............................. 54 
2.5.3 Method ........................................................ ................................................. 55 
2.6 GENE EXPRESSION STUDIES ................................................................................ 55 
2.6.1 Materials ................................................. ..................................................... 55 
2.6.2 RNA and Protein Extraction ........................................................ .................. 56 
2.6.3 Purification of RNA ....................................................................................... 56 
2.6.4 Reverse Transcription of Total RNA to cDNA ................................................ 56 
v 
2.6.5 Analysis ofmRNA Expression by TaqMan® Quantitative Real Time PCR ...... 57 
2.6.6 Primer and Probe Design/or Real-time PCR ................................................. 60 
2.6.7 Real-time PCR Assay ................................................................ .................... 61 
3 Adipokines ................................................................ 64 
3.1 INTRODUCTION .................................................................................................. 64 
3.2 EFFECT OF TISSUE CULTURE PLATE TYPE ............................................................. 64 
3.2.1 Results ... ....................................................................................................... 66 
3.3 MEASUREMENT OF ADIPOKINES .......................................................................... 69 
3.4 EFFECT OF FLAVANOLS ...................................................................................... 71 
3.4.1 Preliminary Concentration Studies ................................................................ 71 
3.4.2 Concentration Range Studies ............................................... .......................... 73 
3.4.3 Effect ofEGCG ................................................ ............................................. 76 
3.5 EFFECT OF MEDIUM GLUCOSE CONCENTRATION ................................................. 78 
3.5.1 Comparison with Rosiglitazone ..................................................................... 79 
3.5.2 Effect of Catechin and EGCG on Adipokine Release ...................................... 80 
3.6 DISCUSSION ............................................................................... ; ....................... 82 
4 Signalling .................................................................. 91 
4.1 INTRODUCTION .................................................................................................. 91 
4.2 PHOSPHORYLATION OF ERK1I2 USING CONTROLS ............................................... 92 
4.3 ERKll2 PHOSPHORYLATION FOLLOWING 1 H FLAVANOL TREATMENT ................... 95 
4.4 ERK1/2 PHOSPHORYLATION FOLLOWING 30 MIN FLAVANOL TREATMENT ............. 97 
4.5 CONFIRMATION OF ERK1I2 PHOSPHORYLATION, USE OF ODYSSEY SYSTEM ........ 102 
4.6 GTPrSBINDINGAsSAY ................................................................................... 103 
4.7 DISCUSSION .. , .................................................................................................. 105 
5 Glucose Uptake ...................................................... 113 
5.1 INTRODUCTION ................................................................................................ 113 
5.2 PRELIMINARY ASSAYS ...................................................................................... 113 
5.2.1 Insulin dose response .................................................................................. 114 
5.2.2 Effect ofCytochalasin B .............................................................................. 114 
5.3 EFFECT OF EPICATECHIN AND EGCG ................................................................ 116 
5.4 DISCUSSION ..................................................................................................... 119 
6 Gene Expression ..................................................... 126 
6.1 INTRODUCTION ................................................................................................ 126 
6.2 METHODS ........................................................................................................ 126 
6.3 RESULTS .......................................................................................................... 128 
6.3.1 Variation Between Housekeeping Genes ................................................. ..... 128 
6.3.2 Expression of Target Genes in Samples ....................................................... 130 
6.3.3 Correlation of Target Gene Expression ............................................ ............ 133 
6.4 DISCUSSION ..................................................................................................... 135 
7 Discussion ............................................................... 141 
8 References ............................................................... 148 
List of Figures 
Figure 1.1 Sequential events during adipocyte differentiation. ........................ 8 
Figure 1.2 Summary ofERK112 MAPKpathway, adaptedfrom Qi and Elion 
(2005) ................................................ ...................................................... ...... 20 
Figure 1.3 Chemical structures of the major flavanols andflavonolsfound in 
green tea ........................................................................................................ 22 
Figure 2.1 Diagrammatic overview of 3T3-Ll differentiation protocol ......... .42 
Figure 2.2 Use offluorogenic probe to enable detection of a specific PCR 
product as it accumulates during PCR cycles ................................................. 58 
Figure 3.1 Effect of plate type on percentage differentiation of 3 T3-L 1 cells. 67 
Figure 3.2 Photographs of cells plated and differentiated on (a) Coming 
Costar ® and (b) Nunclon TML135 mm dishes ................................................. 68 
Figure 3.3 Effect ofplate type on percentage differentiation of 3T3-Ll cells. 68 
Figure 3.4 Representative standard curves for adiponectin (a) and resistin (b) 
from Duosets (R&D Systems) used for analysis of cell culture supernatant .... 70 
Figure 3.5 Effect of 5 pM, 50 pM and 1.5 mM catechin (a) and epicatechin (b) 
on adiponectin release from mature 3T3-Ll adipocytes . ................................ 72 
Figure 3.6 Effect of 5 pM, 50 pM and 1.5 mM catechin (a) and epicatechin (b) 
on res is tin release from mature 3T3-Ll adipocytes . ....................................... 73 
Figure 3.7 Effect of 1, 5 and 10 pM catechin (a) and epicatechin (b) on 
adiponectin release from mature 3T3-Lls . ..................................................... 74 
Figure 3.8 Effect of 1,5 and 10 pM catechin (a) and epicatechin (b) on 
resistin release from mature 3T3-Lls ............................................... .............. 75 
Figure 3.9 Effect of 24 h treatment on adiponectin (a) and resistin (b) release 
from mature 3T3-Ll adipocytes using 1, 5 and 10 pM catechin, epicatechin 
andEGCG ............................................... ...................................................... 77 
Figure 3.10 Adiponectin release from mature 3T3-Ll adipocytes grown on 
Nunclon 35 mm dishes, treated with 10 pM rosiglitazone for 24 h in 12.5 mM 
or 25mM glucose DMEM .............................................................................. 80 
Figure 3.11 Release of adiponectin (a) and resistin (b) from mature 3T3-Ll 
adipocytes grown on Nunclon 35 mm dishes, treated with 10 pM Catechin and 
EGCGfor 24 h in 12.5 mM or 25mM glucose DMEM ................................... 81 
Figure 4.1 Effect on ERK112 and pERK112 following 10mM UO 12 6 (15 min) 
treatment with and without 10nM EGF (10 min) of mature 3T3-Ll cells in 12.5 
mM glucose DMEM ......... .............................................................................. 94 
Figure 4.2 Change in pERK112 levels relative to ERK112 following treatment 
with 10 mM U0126 (15 min) with and without 10 nM EGF (10 min) of mature 
3T3-Ll adipocytes in 12.5 mM glucose DMEM ............................................. 95 
Figure 4.3 Effect on ERK112 and pERK112 following 1 hr treatment of mature 
3T3-Ll s with 10 pAt epicatechin and EGCG in 12.5 mM glucose DMEM ..... 96 
.. 
V11 
Figure 4.4 Change in pERK112levels relative to ERK112following 10 fJM 
epicatechin and EGCG treatment of mature 3T3-L1 cells in 12.5 mM glucose 
DMEM ................................................... ....................................................... 97 
Figure 4.5 Effect on ERK112 and pERK1 12 following 30 minute treatment of 
mature 3T3-L1 cells with 10 and 50 fJM epicatechin in 12.5 mM glucose 
DMEM ................................................... ....................................................... 99 
Figure 4.6 Effect on ERK112 and pERK112 following 30 minute treatment of 
mature 3T3-L1s with 0.1 and 1 fJM EGCG in 12.5 mM glucose DMEM ...... 100 
Figure 4. 7 Change in pERK112 levels relative to ERK112 following treatment 
of mature 3T3-L1 adipocytes with 10 and 50 p.M epicatechinfor 30 min in 12.5 
mM glucose DMEM .................................................................................... 101 
Figure 4.8 Change in pERK112 levels relative to ERK112 following treatment 
of mature 3T3-L1 adipocytesfor 30 min with 0.1 and 1 fJM epicatechin in 12.5 
mM glucose D MEM .................................................................................... 1 01 
Figure 4.9 Effect on ERK112 and pERK112 following 30 minute treatment of 
mature 3T3-L1 cells with 10 fJM epicatechin or 0.1 fJM EGCG in 12.5 mM 
glucose DMEM ........................................................................................... 1 02 
Figure 4.10 GTPyS binding in 10 fJg HEK membrane preparations in the 
presence of 1 0 fJM catechin, epicatechin and EGCG for 90 min. .................. 1 04 
Figure 5.1 2-Deoxyglucose uptake by mature 3T3-L1 adipocytes in 12 well 
plates, in response to varying insulin concentrations (a) and using cytochalasin 
B as an inhibitor (b) ..................................................................................... 115 
Figure 5.2 2-Deoxyglucose uptake by mature 3T3-L1 adipocytes in 12 well 
plates, following 30 min (a), 6h (b) and 24h (c) treatment with either 1, 10 or 
50 fJM epicatechin with and without 10 nM insulin for 10 min. .................... 117 
Figure 5.3 2-Deoxyglucose uptake by mature 3T3-L1 adipocytes in 12 well 
plates, following 30 min (a), 6 h (b) and 24 h (c) treatment with either 0.1, 1 or 
10 J1M EGCG with and without 10 nM insulin for 10 min ............................. 118 
Figure 5.4 Chemical structures of catechin (a), epicatechin (b), kaempferol (c) 
and quercetin (d) . ...................................................... .................................. 120 
Figure 6.1 Correlation between gene expression of 18S rRNA and fJ-actin in 
samples used for TaqMan. ........................................................................... 129 
Figure 6.2 Variation in 18S rRNA (a) and fJ-actin (b) expression between 
treatment groups, measured in arbitrary units (au) . ..................................... 129 
Figure 6.3 Expression of adipsin (a), SREBP (b), FABP4 (c), PEPCK (c), 
adiponectin (e) and PPARy (e) relative to fJ-actin ........................................ 132 
Figure 6.4 Correlation between gene expression ofSREBP and PPARy (a) and 
adiponectin (b) relative to fJ-actin . ............................................................... 133 
Figure 6.5 Correlation between gene expression ofPPARy and FABP4 (a), 
PEPCK (b) and adiponectin (c) relative to fJ-actin. ...................................... 134 
Figure 6.6 Regulation of target genes by ERK112, CIEBPa, CIEBPfJ and 
PPARy . ........................................................................................................ 136 
YIll 
List of Tables 
Table 1.1 Flavonoid subclasses, compounds andfood sources (adaptedfrom 
Beecher, 2003) ................................................. .............................................. 24 
Table 2.1 Details of primary and secondary antibodies used with ECL .......... 50 
Table 2.2 Details of primary and secondary antibodies used with Odyssey 
system ................................................ ............................................................ 51 
Table 2.3 Oligonucleotide sequences ofprimers and probes used in RT-PCR . 
............................................................................................................ .......... 60 
Table 2.4 TaqMan Inventoried Gene Expression Assays (Applied Biosystems) 
...................................................................................................................... 61 
Table 2.5 PCR Master Mix components ........................................................ 61 
Table 2.6 TaqMan cycle details ..................................................................... 62 
Table 3.1 Suppliers of cell culture plates and dishes used ............................. 65 
Table 6.1 Genes measured by TaqMan analysis of 3T3-L1 adipocytes treated 
with 10 pM epicatechin or 0.1 pM EGCG for 6 and 24 h. ............................ 128 
Table 6.2 Comparison of the spread of 18S rRNA and f3-actin gene expression 
in samples usedfor TaqMan analysis ........................................................... 130 
Table 6.3 Amount of target genes adipsin, SREBP, FABP4, PEPCK, 
adiponectin and PPARy2 mRNA, normalised to f3-actin gene expression ...... 131 
IX 
List of Abbreviations 
ADD 1 
aP2 
BAT 
C/EBP 
Cat 
CREB 
DEX 
EC 
ECG 
EGC 
EGCG 
Epi 
ERKl/2 
FABP4 
FAS 
FCS 
FIZZ 
HDL 
HUVEC 
IBMX 
ICAM 
IL-6 
LDL 
LPL 
MAPK 
MEK 
NF-KB 
PAI-I 
PAK 
PEPCK 
PKA 
PKC 
PPARy 
PPRE 
RELMs 
SAA 
SREBP 
TNFa 
TZD 
VCAM 
WAT 
Adipocyte differentiation determination factor 1 
Adipocyte specific fatty acid binding protein 
Brown adipose tissue 
CCAA T I enhancer binding protein 
( + )-Catechin 
cAMP response element binding protein 
Dexamethasone 
(-)-Epicatechin 
(-)-Epicatechin gallate 
(-)-Epigallocatechin 
(-)-Epigallocatechin-3-gallate 
(-)-Epicatechin 
Extracellular signal-regulated protein kinase 112 
Adipocyte specific fatty acid binding protein 
Fatty acid synthase 
Foetal calf serum 
Found in inflammatory zone 
High density lipoprotein 
Human umbilical vein endothelial cells 
Iso butylmethy lxanthine 
Intercellular adhesion molecule 
Interleukin -6 
Low density lipoprotein 
Lipopo lysaccharide 
Mitogen activated protein kinase 
MAPK extracellular signal-regulated kinase kinase 
Nuclear factor-KB 
Plasminogen activator inhibitor-I 
p 21 activated kinase 
Phosphoenol pyruvate carboxykinase 
Protein kinase A 
Protein kinase C 
Peroxisome proliferator activated receptor-y 
Peroxisome proliferator response element 
Resistin like molecules 
Serum amyloid A 
Sterol regulatory element binding protein-lc 
Tumour necrosis factor-a 
Thiazo lidinedio ne 
Vascular cell adhesion molecule 
White adipose tissue 
x 
Introduction 
Introduction 
1 
Introduction 
1 Introduction 
1.1 Adipose tiss ue 
Adipose tissue is our main energy storage organ; it has the ability to retain fat 
following food intake, and release fatty acids and glycerol into the blood 
during starvation. It is specialised connective tissue, a loose association of 
adipocytes held in collagen fibres and also containing leukocytes, macrophages 
and preadipocytes. Humans have two types of adipose tissue, brown adipose 
tissue (BAT) and white adipose tissue (WAT). WAT is the most predominant, 
and in non-obese adult humans, makes up 10-25% of total body weight. It has 
three major functions: to provide thermal insulation, the major role of the 
subcutaneous layer; mechanical cushioning by surrounding the internal organs; 
and fmally as an efficient storage site of excess energy. 60-80% of white 
adipose tissue is made up of lipid, 90-95% of which is triglyceride, the 
remainder comprising of free fatty acids, diglyceride, cholesterol, phospholipid 
and minute quantities of cholesterol ester and monoglyceride are also present. 
Water (5-30%) and protein (2-3%) make up the remaining weight of white 
adipose tissue. 
BAT is scarcer and the general contention was that depots decrease 
significantly in size as humans mature, however recent evidence now suggests 
that adult humans have depots of BAT in the supraclavicular and neck regions, 
with some other additional locations (Nedergaard et al. 2007). BAT derives its 
colour from rich vascularisation and its densely packed mitochondria. In 
hibernating animals and neonates, brown adipose tissue is important for 
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regulating body temperature VIa non-shivering thermogenesis. During 
maturation of non-hibernating animals, including humans, BAT is 
metabolically less active, however activity can be induced by cold exposure. 
The lipids stored in brown adipose tissue release their energy directly as heat. 
(Tong and Hotamisligil2001) 
A new role has emerged for both WAT and BAT as endocrine organs, 
secreting a range ofbioactive polypeptides, known as adipokines. 
1.1.1 Adipose Tissue Development 
Adipocytes originate from fibroblast-like precursors that commit to 
preadipocytes and either stay dormant or, proceed to become differentiated 
adipocytes (Ntambi and Young-Cheul 2000). During terminal differentiation, 
the fibroblast-like preadipocytes undergo a series of morphological and 
biochemical changes to eventually accumulate lipid droplets (Tong and 
Hotamisligil 2001). The size of adipose tissue IS a function of adipocyte 
number and size. An increase in adipose tissue can occur by either 
hyperplastic growth (increased adipocyte number) or hypertrophic growth 
(increased adipocyte size), caused by this lipid accumulation. 
Adipose tissue differs from other tissues in the body in that it occurs in 
multiple, dispersed sites around the body, mostly in areas rich in loose 
connective tissues. Differentiation of preadipocytes to mature adipocytes 
occurs in clusters, possibly suggesting the expression of a recruitment factor by 
mature adipocytes (Rosen and Spiegelman 2000). The absence of a clear 
3 
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molecular marker for adipogenesis, along with the diffuse nature of adipose 
tissue has made it difficult to isolate and study preadipocytes. The earliest 
event associated with adipogenesis is a proliferating network of capillaries in 
an otherwise undistinguished region of subcutaneous tissue. This shows that 
there is an important link between adipogenesis and angiogenesis, however it is 
still unclear how they induce each other. Foetal adipocytes and their associated 
endothelial cells express many of the same cell surface markers, which implies 
a common line of descent (Rosen and Spiegelman 2000). 
The two models that have been frequently used to study adipose tissue are 
adipocytes differentiated either from immortalised preadipocyte cell lines in 
culture or obtained from stromal-vascular cells in adipose tissue (Tong and 
Hotamisligil 2001). The establishment of these in vitro cellular models for 
adipogenesis has greatly advanced the understanding of the molecular basis of 
differentiation. The most extensively characterised preadipocyte lines are the 
3T3-Ll and 3T3-F442A lines, isolated from non-clonal murine Swiss 3T3 cells 
by Green, Meuth and Kehinde (Green and Meuth 1974; Green and Kehinde 
1975). These cells are morphologically indistinguishable from fibroblasts but 
are already committed to the adipocyte lineage. When treated with pro-
differentiative agents (cyclic adenosine monophosphate (cAMP), insulin and 
glucocorticoids) they undergo differentiation over a 4-6 day period to form 
mature fat cells. This is thought to represent a valid model of preadipocyte 
differentiation in vivo, as indicated by transplantation studies. When 3T3-
F442A preadipocytes were injected subcutaneously into Balb-C athymic mice, 
normal fat pads developed at the site of injection within 5 weeks (Green and 
Kehinde 1979). Additionally, evidence shows that the fully differentiated 
4 
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adipocytes mimic the metabolism of adipocytes isolated from adipose tissue. 
Preadipocytes in culture also acquire the proteins necessary for lipolysis of 
triacylglycerol, uptake and intracellular translocation of fatty acids, and 
regulation of these processes by lipogenic and lipolytic hormones. Finally, 
detailed electro-micrographic studies have verified that mature 3T3-Ll 
adipocytes possess the ultrastructural features of adipocytes in vivo, such as the 
occurrence of constellations composed of large triacylglycerol droplets 
bordered by the endoplasmic reticulum and closely associated with 
microperoxisomes and mitochondria. These constellations are thought to serve 
as foci for the biosynthesis, accumulation and metabolism of adipocyte lipid 
(Novikoff et al. 1980). 
There are, however, several potential drawbacks to the exclusive use of 
established preadipocytic cell lines in studies of adipogenesis, including their 
aneuploid status, which may influence their competence to undergo 
differentiation, and the fact that they exist out of the context of their normal 
extracellular matrix and supporting structures. Another important limitation is 
that they do not allow the assessment of depot-specific differences in fat cell 
behaviour. In vivo, white adipose tissue is located in a variety of locations, 
including omental, retroperitoneal, and subcutaneous depots. Preadipocytes 
isolated from different areas have different adipogenic potential. Additionally, 
the metabolic behaviour of mature fat cells differs from depot to depot. 
------- --------------------------
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1.1.2 Regulation of Adipogenesis 
Although the signals which initiate in vivo adipogenesis are still unknown, a 
combination of hormones such as insulin, glucocorticoids and cAMP-
generating agents have been demonstrated to effectively promote the terminal 
differentiation of cultured preadipocyte cells. The role of insulin is to increase 
the percentage of cells that differentiate and increase the amount of lipid 
accumulation in each fat cell (Rosen and Spiegelman 2000). Insulin affects 
differentiation by cross-activating the IGF-l receptor. Activation of the IGF-l 
receptor is essential for preadipocytes to acquire their adipocyte morpho 10 gy 
and accumulate lipid droplets (Smith et at. 1988). This is paralleled with the 
increase in activity of glycerol-3-P dehydrogenase, a sensitive indicator of 
adipocyte development (Wise and Green 1979). IGF-l and insulin also 
activate several distinct downstream signal transduction pathways including ras 
and protein kinase B, which may mediate their adipogenic effects (Rosen and 
Spiegelman 2000). Glucocorticoids, usually in the form of dexamethasone, are 
used to activate the glucocorticoid receptor. The transcriptional targets 
involved are unclear, but induction of CCAAT/enhancer binding protein-8 
(C/EBP8) may be a possible mechanism. Addition of methylisobutylxanthine 
(lBMX) to cultured preadipocytic cell lines has been shown to enhance 
differentiation (Rosen and Spiegelman 2000). IBMX is a phosphodiesterase 
inhibitor, which can elevate intracellular levels of cAMP. Protein kinase A 
(PKA) is the main target of cAMP, and both cAMP and PKA have been 
implicated in the regulation of lipid accumulation (Spiegelman and Green 
1981; Zhang et al. 2002). 
6 
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Thiazolidinediones (TZDs) have also been shown to influence adipocyte 
differentiation as they are peroxisome proliferator activated receptor-y 
(PP ARy) agonists. Several genes implicated in adipocyte differentiation 
contain PP AR response elements (PPREs), including adipocyte specific fatty 
acid binding protein (aP2/F ABP4) and lipoprotein lipase (LPL). PP ARy 
knockout mice studies have shown that PP ARy -1+ mice are characterised by 
decreased adipose tissue mass (Kubota et al. 1999; Miles et al. 2000). 
Upon hormonal stimulation, cultured preadipocytes undergo several rounds of 
proliferation and then succumb to growth arrest. During this period, the 
expression of C / E B P ~ ~ and C/EBP8 has a temporal rise, followed by the 
stimulation of expression of PP ARy and C/EBPa. There is a positive feedback 
loop between PP ARy and C/EBPa where both factors induce the expression of 
the other. A generally cooperative action between PP ARy and C/EBPa drives 
the expression of genes that are necessary for the generation and maintenance 
of the adipogenic phenotype. These genes include, among others, aP21F ABP4, 
phosphoeno lpyruvate carboxykinase (PEPCK), glycero lphosphate 
dehydrogenase, fatty acid synthase (F AS), acyl CoA carboxylase, GLUT4 and 
the insulin receptor (Tong and Hotamisligil 2001). Additionally, sterol 
regulatory element binding protein (ADD IISREBP 1) plays a role in 
adipogenesis by activating PP ARy transcription and controlling the production 
of endogenous PP ARy ligands (Kim et al. 1998). This is summarised in Figure 
1.1. 
The cAMP responsive transcription factor CREB has also been found to playa 
role in adipogenesis. Hormonal induction of 3T3-L1 differentiation activates 
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CREB phosphorylation and transcriptional activity. The expressIOn of 
constitutively active CREB in 3T3-LI cells induces adipocyte differentiation, 
and the expression of dominant-negative form of CREB blocks adipogenesis. 
CREB may exert its function by binding to and activating the promoters of 
C / E B P ~ ~ and C/EBP8 and several other genes, such as PEPCK, F AS and 
aP2/F ABP4 (Reusch et al. 2000). 
Honnonal 
stimulation: 
-Insulin 
-DEX 
-IBMX 
'" { C / E B P ~ } }
C/EBPo 
Ligand 
C/EBPa. 
I 
PPARy 
ADD lISREBP 1 
Figure 1.1 Sequential events during adipocyte differentiation. 
Adipocyte gene 
expresSlon 
Hormonal stimulation by insulin, dexamethasone and methylisobutylxanthine, 
initiates the adipogenic program involving sequential activation of the CIEBP 
family of transcription factors and PPARy and the eventual expression of a 
large set of adipogenic genes such as aP2IFABP4, FAS, PEPCK and leptin. 
ADD 1 ISREBP 1 is a transcription factor that can activate P P ARy transcription 
and produce ligandsfor PPARy. Adaptedfrom Tong and Hotamisligil (2001). 
Terminal differentiation is generally coupled to growth arrest, as in the case in 
adipocyte differentiation. Both PPARy and CIEBPa possess anti proliferation 
properties (Rosen et al. 2000). Adipogenesis is also associated with a transient 
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activation of cyclin expression, and changes in the expression of several cyclin 
dependent kinase inhibitors such as p18 and p21 (Morrison and Farmer 1999). 
ERK1I2 is regulated at various stages throughout the differentiation process 
and is regulated by insulin and growth factors - it is turned on for proliferation 
early on, and then switched off to avoid PP ARy phosphorylation. Additionally, 
ERK1I2 activity is necessary for the expression of the crucial adipogenic 
regulators C/EBPa, ~ , , and 8 (Prusty et al. 2002). 
1.2 Adipokines 
Adipokines are bioactive peptides and proteins secreted by both brown and 
white adipose tissue; however, as white adipose tissue comprises 10-25% of 
the total body weight of non-obese humans, adipokines secreted by it are 
thought to have greater influence than those secreted by brown adipose tissue. 
Adipokines represent a diverse group of enzymes (adipsin), growth factors 
(vascular endothelial growth factor), cytokines (tumour necrosis factor-a (TNF 
a) and interleukin-6 (IL-6) and other hormones (leptin, adiponectin, resistin 
and acylation stimulation protein), which play a critical role in energy 
regulation and carbohydrate and lipid metabolism (Mora and Pessin 2002). 
Only leptin, adiponectin, resistin, adipsin and visfatin are primarily produced 
by adipocytes and can therefore be properly classified as adipokines (Fantuzzi 
2005). Adiponectin and resistin are the adipokines investigated in this study, 
and so they shall be explored in further detail. 
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1.2.1 Adiponectin 
Adiponectin, also known as adipocyte complement-related protein of 30 kDa 
(Acrp30), adipose most abundant gene transcript 1 (apMl), adipoQ and gelatin 
binding protein of 28 kDa (GBP28), was identified as a protein expressed and 
secreted by differentiated 3T3-Ll adipocytes and also found to be in abundant 
quantity in serum (Scherer et al. 1995). It was independently cloned as 
AdipoQ by differential display of murine mRNAs among non-adipogenic 3T3-
C2 fibroblasts, undifferentiated 3T3-F442A preadipocytes, and differentiated 
3T3-F442A adipocytes (Hu et al. 1996). It is an approximately 30 kDa 
polypeptide containing an N-terminal sequence, a variable domain, a collagen-
like domain and a C-terminal globular domain (Kershaw and Flier 2004). 
Post-translational modification by hydroxylation and glycosylation produces 
multiple isoforms, which assemble into trimers and then into higher-order 
oligomeric structures composed of four to six trimers (Fantuzzi 2005). Both 
trimers and oligomers, but not monomers, of adiponectin are present in the 
circulation (Fantuzzi 2005). A proteolytic cleavage product containing the 
globular domain of adiponectin also circulates at physiologically significant 
levels and has biological activity (Kershaw and Flier 2004). 
Adiponectin is expressed exclusively in white adipose tissue and adipocytes are 
the most important source of adiponectin, but serum adiponectin levels do not 
increase with obesity. Serum adiponectin levels are low in obese subjects but 
increase with weight loss (Lyon et al. 2003). Adiponectin is distinct from 
other known adipokines in that it appears to improve insulin sensitivity and 
inhibit vascular inflammation. The mechanism by which the insulin-resistant 
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state is associated with low adiponectin levels is not clear. TNF u. which is 
increased in the white adipose tissue of obese subjects, might down-regulate 
adiponectin production (Fantuzzi 2005). However, adiponectin reduces the 
production and activity of TNF u, IL-6 and nuclear factor (NF)-KB (Fantuzzi 
2005). 
In the liver, adiponectin enhances insulin sensitivity, decreases influx of non-
esterified fatty acids (NEF As), increases fatty acid oxidation, and reduces 
hepatic glucose output. In muscle, adiponectin stimulates glucose utilisation 
and oxidation of fatty acids. Within the vascular wall, adiponectin inhibits 
monocyte adhesion by decreasing the expression of the adhesion molecules 
intercellular adhesion molecule-l (ICAM-l) and vascular cell adhesion 
molecule (VCAM-l) by either TNF-u or resistin (Fantuzzi 2005). Adiponectin 
also inhibits macrophage transformation to foam cells by inhibiting expression 
of scavenger receptors and decreases proliferation of migrating smooth muscle 
cells in response to growth factors. In addition, adiponectin increases nitric 
oxide production in endothelial cells and stimulates angiogenesis. All of these 
effects are mediated via: increased phosphorylation of the insulin receptor; 
activation of AMP-activated protein kinase in skeletal muscle and liver to 
increase fatty acid oxidation and reduce hepatic glucose production; and 
modulation of the NF-KB pathway (Guerre-Millo 2004; Kershaw and Flier 
2004). 
Adiponectin administration to animals enhances insulin action, and low levels 
of adiponectin have been proposed to contribute to insulin resistance associated 
with obesity. Adiponectin gene expression and circulating adiponectin levels 
I I 
Introduction 
are lower in patients with type 2 diabetes than in non diabetic individuals 
(Havel 2004). Adiponectin mRNA is decreased three fold in ob/ob mice 
compared to wild type littermates (Haluzik et al. 2004). 
Adiponectin receptors 1 and 2 (AdipoRl and AdipoR2) have been identified. 
These receptors contain seven-trans-membrane domains but are structurally 
and functionally distinct from G protein coupled receptors. AdipoRl is 
expressed primarily in muscle, and functions as a high affmity receptor for 
globular adiponectin and a low affmity receptor for full-length adiponectin. 
AdipoR2 is expressed primarily in the liver, and functions as an intermediate 
affmity receptor for both globular and full-length adiponectin. The tissue 
specific expression of the receptor subtypes, the properties of the different 
adiponectin isoforms as well as their circulating levels are all responsible for 
the biological effects of adiponectin. (Kadowaki et al. 2006) 
1.2.2 Resistin 
Resistin is an adipokine with contrasting roles in mice and man. It was initially 
shown to be released in large amounts from mouse adipocytes; its release was 
increased in obese mice and accompanied by insulin resistance, implying that 
adipocyte-derived resistin linked obesity to diabetes. Resistin is secreted by 
mature adipocytes and has an inhibitory effect on insulin-stimulated glucose 
uptake in differentiated 3T3-Ll adipocytes, and the inhibitory effect is 
prevented by an anti-resistin antibody (Steppan et al. 200 I). Ablation of the 
resistin gene m mice decreases fasting glucose through reducing 
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gluconeogenesis, while resistin administration in these resistin-deficient mice 
increases hepatic glucose production (Banerjee et al. 2004). These studies 
indicate that resistin impairs insulin sensitivity and may contribute to the 
development of insulin resistance or diabetes in obese rodents. 
Resistin is encoded by the retn gene (Steppan et al. 2001). Serum levels have 
been found to be elevated in both obesity (Degawa-Yamauchi et al. 2003) and 
diabetes (McTernan et al. 2003; Fujinami et al. 2004), implicating that resistin 
is dysregulated in these conditions. Resistin gene expression is also increased 
2.2 fold in obesity (Li et al. 2002). 
Resistin is not found in human adipocytes, but it is found in the monocytes 
within adipose tissue (Nagaev and Smith 2001). However, in mice it is thought 
that resistin is secreted by adipocytes into the blood circulation. Resistin 
opposes the actions of insulin in adipocytes and liver, causing increased 
glucose production by the liver and inhibiting differentiation of preadipocytes 
to adipocytes. Increased dietary fat and obesity increase the expression of 
resistin in adipocytes. 
Studies in vitro have shown that resistin is induced during adipocyte 
differentiation and is secreted into media (Steppan et al. 2001). A family of 
related proteins (called resistin like molecules [RELMs] or found in 
inflammatory zone [FIZZ]) were revealed via database searching using the 
resistin cDNA sequence (Steppan et al. 2001). FIZZ 1 and FIZZ2 are 
homologous to the mouse RELMa and R E L M ~ ~ respectively and resistin is 
alternatively known as FIZZ3 (Steppan et al. 2001). Although the other 
RELMIFIZZ family members exhibit tissue-specific expression, resistin is the 
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only one of these family members to be expressed ill mouse adipocytes 
(Hartman et al. 2002). 
Resistin is secreted as a dimer (Banerjee and Lazar 200 I), and studies suggest 
that it forms higher order multimeric complexes with other dimers or the other 
RELMs (Chen et al. 2002), in a similar way to adiponectin. Resistin 
expression in visceral fat is 15-fold higher than in subcutaneous fat (Gabriely et 
al. 2002). Visceral fat has been identified as a risk factor for insulin resistance 
and increased levels of visceral fat are correlated with decreased insulin 
sensitivity (Gabriely et al. 2002; Goldstein 2002). 
Resistin inhibits the differentiation of3T3-LI preadipocytes (Kim et al. 2001). 
It has been suggested that resistin plays a role in inflammatory conditions as it 
is expressed in human macrophages (N agaev and Smith 200 I; Savage et at. 
2001) and RELMa/FIZZI is up-regulated by inflammation in the mouse. 
However, resistin is down regulated by inflammatory mediators such as TNFa 
and lipopolysaccharide (LPS) (Hartman et at. 2002). 
Resistin is secreted from murine adipocytes and antagonises insulin-stimulated 
glucose metabolism in skeletal muscle myocytes, hepatocytes, and adipocytes 
themselves. (Shojima et al. 2002). Resistin gene expression is induced during 
adipocyte differentiation in culture and is restricted to W A T and to BAT in 
vivo. (Walczak and Tontonoz 2002) 
1.3 Adipokine Regulation 
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Adipokine dysregulation is one of the key features of obesity and associated 
insulin resistance. It is therefore important to try and understand how the 
adipokines are regulated, how dysregulation is caused and the ways in which 
this may be corrected. 
Adiponectin and resistin are the two adipokines that are the focus of these 
studies, therefore, only the regulation of these two will be further described. 
1.3.1 Regulation of Adiponectin 
There is a general hypothesis that adiponectin plays a significant role in linking 
obesity and insulin resistance, leading ultimately to Type 2 diabetes and 
atherosclerosis. Several clinical studies have observed that circulating 
adiponectin levels are reduced in obesity, in which mean adipocyte size is 
increased, and increased in lean individuals with smaller adipocyte size. A 
situation of low circulating adiponectin levels then promotes increased cellular 
lipid content and insulin resistance in skeletal muscle and liver. 
Adiponectin gene expression is regulated by several extracellular signalling 
factors, including insulin, TNFa and ~ - a d r e n e r g i c c agonists (Havel 2004), 
although the link between these signals and adiponectin gene expression, in 
most cases, has yet to be elucidated. PP ARy has been shown to induce 
adiponectin promoter activity though an unidentified element responsive to 
PPARy (Maeda et al. 2001). TZDs (thiazolidinediones) are a class of synthetic 
drugs, which include rosiglitazone, pioglitazone, troglitazone and darglitazone. 
TZDs were identified clinically as drugs that lower blood glucose and insulin 
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levels, leading to improved insulin sensitivity in Type 2 diabetic patients (Day 
1999; Reginato and Lazar 1999). TZDs are high affmity ligands for PP ARy 
(Willson et al. 2001). TZD agonists ofPPARy increase adiponectin expression 
and circulating levels in rodents, and plasma adiponectin levels in non-diabetic 
subjects and in patients with Type 2 diabetes. In addition, the improvement of 
insulin sensitivity during TZD treatment was related to the increase in 
circulating adiponectin. It is possible that the effects of TZDs to increase 
whole body insulin sensitivity and to protect against cardiovascular disease 
could be mediated by increased adiponectin production (Havel 2004). Another 
potential mechanism of action of the TZDs is the "lipid steal hypothesis" (Ye 
et al. 2006), in which excessive lipid accumulation in muscle and liver is 
reduced by redistributing circulating lipids to adipose tissue. 
C/EBPa has been reported to regulate adiponectin gene transcription through 
an intronic enhancer (Qiao et al. 2005). SREBP-1c binds to the adiponectin 
promoter and mediates the insulin-dependent adiponectin expression (Seo et al. 
2004). Kruppellike factor (KLF)-7 has been reported to inhibit adiponectin 
gene expression in adipocytes (Kawamura et al. 2006). 
1.3.2 Regulation of Resistin 
Most mouse studies support the notion that resistin is an adipokine regulator of 
insulin action. However, most human studies show an entirely different 
picture. Human fat cells, unlike those of mice, do not produce resistin, 
although segments of human adipose tissue do release it. Resistin was 
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originally thought to be an adipokine because it is produced by adipocytes and 
causes insulin resistance in rodent models. However, subsequent human 
studies failed to link resistin to insulin resistance. In addition, the protein is not 
produced by human fat cells but by some yet unidentified cell in the stroma of 
human adipose tissue, which might be the macrophage (Bokarewa et al. 2005). 
In humans, it appears that peripheral blood mononuclear cells and 
macrophages are the major source of resistin rather than the adipocyte; this 
may explain why resistin mRNA expression is relatively low in human 
adipocytes (Yang et al. 2003). Moreover, as resistin levels do not consistently 
correlate with insulin resistance or obesity (Janke et al. 2002), the role of 
human resistin in the pathogenesis of insulin resistance is unclear. 
Treatment of3T3-L1 adipocytes with insulin was found to significantly reduce 
resistin mRNA and protein levels (Haugen et al. 2001; Shojima et al. 2002), 
additionally, in vivo studies have shown that insulin administration reduced 
resistin (Kim et al. 2001). 
TZDs, by activating PPARy, cause decreased resistin expression and decreased 
insulin resistance (Wolf 2004). Treatment of mice with TZDs lowered resistin 
protein levels, similar to the effects observed in vitro, using 3T3-L1 cells 
(Steppan et al. 2001). 
Resistin is up-regulated several fold following dexamethasone treatment in 
vitro (Shojima et al. 2002), however it is unclear whether this up-regulation is 
independent of dexamethasone stimulated adipogenesis. Treatment of mice 
with dexamethasone induces resistin in white adipose tissues (Shojima et al. 
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2002). Additionally, resistin levels are suppressed by adrenaline and 
somatotrophin (Shojima et al. 2002). 
The mechanisms of adiponectin and resistin regulation have not been fully 
elucidated as yet, however they are both altered by TZD treatment and 
therefore are under the control of PP ARy phosphorylation. PP ARy is a 
substrate of ERK1I2, and there is evidence to suggest that phosphorylation 
decreases its transcriptional activity (H u et al. 1996; Adams et al. 1997; Camp 
and Tafuri 1997; Reginato et al. 1998; Chan et al. 2001). This suppression of 
PP ARy activity can result in increased adiponectin release and suppression of 
resistin release in adipocytes, shown recently by Sharma and Staels (Sharma 
and Staels 2007). 
1.4 Role of MAPK 
In addition to the role of the mitogen activated protein kinase (MAPK) ERK1I2 
in mediating adiponectin and resistin release via PP ARy, ERK1I2 also plays a 
crucial role in adipogenesis, as detailed in 1.1.2. For this reason, the ERK1I2 
pathway will be further explored. 
MAPKs comprise a family of protein kinases whose function and regulation 
have been conserved during evolution from unicellular organisms to complex 
organisms including humans. MAPKs phosphorylate specific serines and 
threonines of target protein substrates and regulate cellular activities ranging 
from gene expression, mitosis, movement, metabolism, and programmed death. 
The MAPK family is an essential part of the signal transduction machinery in 
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signal transmissions from cell surface receptors and environmental stimulation. 
Because of the many important cellular functions controlled by MAPKs, they 
have been studied extensively to defme their roles in physiology and human 
disease. 
There are five subfamilies of MAPKs, these are extracellular signal-regulated 
kinases (ERK) 1 and 2, the c-Jun NH2-terminal kinases (JNK) 1 and 2, p38 
enzymes, ERK 3 and 4 and ERK 5. 
1.4.1 The ERK1/2 MAPK Pathway 
The most well characterised pathway is the ERK1I2 pathway (Ray and Sturgill 
1987). This pathway plays an essential role in cell proliferation and its role in 
normal and pathological adipogenesis has been intensively investigated since 
1991, when the first paper demonstrating a link between ERK1I2 and adipocyte 
differentiation was published (Benito et al. 1991). The ERK1I2 pathway is 
important in regulating the cell cycle and cell proliferation and, as such, is 
activated by growth factors and insulin. The relevance of this pathway is that 
obesity is characterised by hypertrophy of adipocytes and the recruitment of 
new adipocytes from precursor cells. These processes are dependent on 
adipocyte differentiation. ERK1I2 is regulated at various stages throughout the 
differentiation process - it is turned on for proliferation early on, and then 
switched off to avoid PP ARy phosphorylation. Additionally, ERK1I2 activity 
is necessary for the expression of the crucial adipogenic regulators C/EBPa, ~ , ,
and 8 (Prusty et al. 2002). The potential modulation of the ERK1I2 MAPK 
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pathway by flavanols is therefore significant, considering the role it plays in 
obesity. 
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Figure i.2 Summary of ERKil2 MAPK pathway, adapted from Qi and Elion 
(2005). 
Ligands bind to cell surface receptor tyrosine kinases, integrins or G-protein 
coupled receptors (GPCRs). This leads to activation of protein kinase A 
(PKA) , protein kinase C (PKC) via phospholipase C (PLC), p2i activated 
kinase (P AK) or Ras GTP. This then triggers activation of Raf isoforms, 
followed by phosphorylation of lYlEKil2 and then ERKiI2. 
ERKi 12 have many known targets, including key transcription factors such as 
AP-i (activating protein-i), NF-KB (nuclear factor- KB), Myc and MSK 
(mitogen- and stress-activated protein kinase). References are (1) (Karin et al. 
i997), (2) (Gilmore 2006), (3) (Telfer et al. 2005), (4) (Hauge and Frodin 
2006). 
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MAPK pathways comprise a four tiered kinase cascade comprising a MAP 
kinase kinase kinase kinase (MAP4K), a MAP kinase kinase kinase (MAP3K), 
a MAP kinase kinase (MEK) and fmally the MAPK. 
In the ERK1I2 MAPK pathway there are several MAP4Ks; (protein kinase A 
(PKA) , protein kinase C (PKC) and p21 activated kinase (PAK)) which 
activate the RafMAP3Ks (A-Raf, B-Raf, C-Ra£'Raf-l). Alternatively, the Raf 
isoforms can be activated by Ras, a small GTP-binding protein. Raf is then 
recruited to the plasma membrane, followed by phosphorylation of 
MEKIIMEK2 and then ERKI and ERK 2. (Qi and Elion 2005). The ERK1/2 
MAPK pathway is summarised in Figure 1.2. 
1.5 Green Tea Catechins 
Tea, from the plant Camellia Sinensis, is the most consumed drink in the world 
after water. Depending on the manufacturing process, teas are classified into 
three major types: 1) non fermented green tea; 2) semi-fermented oolong tea; 
and 3) fermented black and red teas (Cabrera et al. 2006). 
Green tea is produced by steaming freshly harvested leaves to prevent 
fermentation, yielding a dry, stable product. Tea polyphenols, known as 
catechins or flavanols, usually account for 30-42% of the dry weight of the 
solids in brewed green tea (Khan and Mukhtar 2007). The four major flavanols 
are (-)-epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin (EGC), (-)-
epicatechin-3-gallate (ECG) and (-)-epicatechin. EGCG is the major flavanol 
and may account for 50-80% of the total catechin in tea. Green tea also 
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contains (+)-catechin, kaempferoL myricetin and quercetin. The structures of 
these are shown in Figure 1.3. 
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Figure 1.3 Chemical structures of the major flavanols and flavonols found in 
green tea. 
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Flavonoids belong to a vast group of polyphenolic compounds that are widely 
distributed in all foods of plant origin. Plant polyphenols have been of interest 
to scientists for decades, originally owing to their importance in plant 
physiology, specifically for their roles in plant pigmentation and flavour. 
Polyphenols are involved in plant growth and reproduction, provide resistance 
to pathogens and predators, and protect crops from disease and preharvest seed 
germination. 
1.5.1 Nomenclature 
The catechins belong to a group known as the flavanols, a subclass of the 
flavonoid polyphenols. More than 5000 different flavonoids have been 
described. The six major subclasses of flavonoids are the flavanols, 
flavanones, flavones, isoflavones, flavonols and anthocyanidins. Table 1.1 lists 
the flavonoid subclasses, the compounds within that class, and primary food 
sources. The common structure of flavonoids involves two aromatic rings 
linked through three carbons that typically form an oxygenated heterocycle. 
Flavonoids are classified into categories according to the oxidation level of the 
central heterocyclic ring. Within each subclass, individual compounds are 
characterised by specific hydroxylation and conjugation patterns (Beecher 
2003). 
It has been calculated that a cup of green tea, comprising 2.5 g of green tea 
leaves/200 ml of water, may contain 90 mg of EGCG (Wu and Wei 2002). 
Pharmacokinetic studies by Ullmann et al reveal that a bulk dose of 100 mg 
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EGCG resulted in a maximum plasma concentration of 189.52 nglml (0'-+ 11M) 
and a bulk dose of 1600 mg EGCG was required to produce a maximum 
plasma concentration of 2911.35 ng/ml (6.35 11M) free EGCG (Ullmann et al. 
2003) 
Chow et al carried out a Phase I pharmacokinetic study in humans to determine 
the systemic availability of EGCG after a single oral dose administration of 
200, 400, 600 or 800 mg. The maximum plasma concentrations were 73.7, 
111.8,169.1 and 438.5 ng/ml (0.16,0.24,0.37 and 0.96 11M) for each dose 
level respectively, 4 h after administration (Chow et al. 2001). 
Table 1.1 Flavonoid subclasses, compounds and food sources (adaptedfrom 
Beecher, 2003). 
Subclass Compounds Primary food sources 
Flavanols (+ )-Catechin, (+ )-gallocatechin, (-)- Green tea, black tea, 
epicatechin, (-)-epigallocatechin, (-)- grapes and red wines 
epicatechingallate, (-)-epigallocatechingallate, 
Flavanones Hesperetin, naringenin, eriodictyol Oranges, grapefruits, 
lemons 
Flavones Luteolin, apigenin Apples, celery, celeriac, 
lemons, parsley 
Isoflavones Genistein, diadzein, glyceitein, biochanin A, Soybeans, legumes 
formononentin 
Flavonols Quercetin, kaempferol, myricetin, isorhamnetin Onions, apples, teas, 
berries, olives, bananas, 
lettuce, plums, red wine 
Anthocyanidins Cyandin, delphinidin, malvidin, pelargonidin, Blueberries, raspberries, 
peonidin, petunidin strawberries, cranberries 
24 
Introduction 
1.5.2 Flavanol Content of Green Tea and Bioavailability 
A study by Yang et al investigating the time dependent plasma concentrations 
and urinary excretion of 1.5 g decaffeinated tea solids dissolved in 500 ml 
water demonstrated that the maximum plasma concentrations of EGCG, EGC 
and Ee were 326, 550 and 190 ng/ml respectively and these were observed 
1.4-2.4 hours after ingestion of the tea preparation. When the dosage was 
increased from 1.5 to 3 g, the maximum plasma concentrations increased 2.7-
3.4 fold, but increasing the dose to 4.5 g did not significantly increase the 
maximum plasma concentrations, suggesting a saturation point may have been 
reached. The half-life ofEGCG was much longer than that ofEGC or EC (5-
5.5 hours compared to 2.5-3.4 hours), and EGC and EC, but no EGCG were 
excreted in the urine (Yang et al. 1998). 
Investigation into the degradation of 0.5 g catechin per day over a 3 week 
period in male Wistar rats revealed that only 3.1 % of the ingested catechin was 
excreted unchanged in the faeces, suggesting the catechin had either been 
absorbed, degraded or metabolised (Bravo et al. 1994). 
1.5.3 Flavanol Metabolism 
Flavanols are extensively metabolised in vivo - the bioactive forms of the 
flavanols in plants are glycosides (bound to sugar), when they are not attached 
to sugar moieties they are referred to as the aglycone form. Except for 
flavanols, flavonoid molecules do not occur in plants as aglycones; the most 
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frequently occurrmg forms are the glycoside derivatives m plants. 
Glycosylation increases the polarity of the flavonoid molecule, which IS 
necessary for storage in plant cell vacuoles (Aherne and O'Brien 2002). 
Upon intestinal absorption, conjugates and metabolites are formed from the 
glycosides. In particular, there is strong evidence for the extensive phase I 
deglycosylation and phase II metabolism of the resulting aglycones such as 
epicatechin to glucuronides, sulphates and O-methylated forms during transfer 
across the small intestine and then again in the liver. Further transformation 
has been reported in the colon, where the enzymes of the gut micro flora 
degrade flavanols to simple phenolic acids, which may also be absorbed and 
subsequently further metabolised in the liver (Williams et al. 2004). 
Following these phase I and II deglycosylations and metabolisms, there are 
three forms of intracellular metabolism that flavanols may undergo. These are 
1) conjugation with thiols, particularly GSH, 2) oxidative metabolism, and 3) 
P450 related metabolism. These metabolic modifications will alter the 
flavanols' classical antioxidant nature, i.e. their ability to donate electrons to 
stabilise radical species and bind transition metals. Circulating metabolites of 
flavanols, such as glucuronides and O-methylated forms, and intracellular 
metabolites, for example flavanol-GSH adducts, have a reduced ability to 
donate hydrogen and are less effective scavengers of reactive oxygen and 
nitrogen species relative to their parent aglycone forms. Concentrations of 
flavanols and their metabolite forms accumulated in the plasma are lower (high 
nanomolar, low micromolar) than those recorded for small molecule 
antioxidant nutrients such as ascorbic acid and a-tocopherol. Consequently. 
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flavanols are unlikely to express beneficial actions In VIVO through 
outcompeting antioxidants such as ascorbic acid which are present at higher 
concentrations (high micromolar). Accumulating evidence suggests that the 
cellular effects of flavanols may be mediated by their interactions with specific 
proteins central to intracellular signalling cascades. (Williams et al. 2004) 
1.5.4 Interactions with ERKl/2 Pathway 
There is evidence to suggest that flavanols can influence the phosphorylation 
status ofERK1I2. A study by Hung et al in 3T3-Ll preadipocytes showed that 
50 /-lM EGCG was able to decrease ERK1I2 phosphorylation after 30 min, and 
this was maintained at 1 and 4 hour treatment times, and through this was able 
to decrease proliferation of the preadipocytes (Hung et al. 2005). As obesity is 
the result of both increased adipocyte size (hypertrophy) and increased 
adipocyte number (hyperplasia) the anti mitogenic effect suggests that EGCG 
may be able to modulate obesity. 
In human umbilical vein endothelial cells (HUVECs) 30-50 /-lM EGCG was 
able to inhibit angiotensin II induced ERK1I2 phosphorylation and therefore 
prevent increases in protein and mRNA levels of vascular cell and intercellular 
adhesion molecules (VCAMs and ICAMs) (Chae et al. 2007). Studies in 
human keratinocytes showed that ECG was able to inhibit hydrogen peroxide-
induced ERK1I2 phosphorylation, thus protecting keratinocytes from lipid 
peroxidation and cell death (Huang et al. 2007). 
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The effects of a wide range of flavonoids have been investigated in neurons, 
where they are thought to have a neuroprotective effect, interacting with 
MAPK pathways as they are involved in signalling to neuronal survival, 
regeneration and death. The flavanol effects on ERK1I2 phosphorylation have 
been investigated in primary cortical neurons where epicatechin at 100-300 nM 
was able to stimulate ERK1I2 phosphorylation (Schroeter et al. 2007). The 
flavonol quercetin, inhibits ERK1I2 phosphorylation in the same system after 
30 min incubation at concentrations of 0.3-30 IlM (Spencer et al. 2003). A 
further study using cortical neurons showed that hesperetin, a flavanone, was 
able to increase ERK1I2 phosphorylation at 100 nM (Vauzour et al. 2007). 
It is clear that the various flavonoids are able to alter the phosphorylation status 
of ERK 112 , but not necessarily in the same direction. It is therefore difficult to 
predict what effect the green tea catechins might have on the phosphorylation 
status of ERK1I2 in 3 T3-L 1 adipocytes, because although they decrease 
phosphorylation in preadipocytes, these cells are very different to the mature, 
differentiated adipocytes. 
It has been suggested that the 67 kDa Laminin Receptor (LR) is a receptor for 
EGCG, however, this was discovered on cancer cells (Tachibana et al. 2004) 
and receptors for laminin have been found on muscle, epithelial and nerve 
cells, macrophages, neutrophils and hepatocytes (Mecham 1991), but to date, 
none have been identified on adipocytes. Laminin serves as a major adhesion 
substrate for invasive cancer cells, and human melanoma cells expressing a 
reduced level of 67 kDa LR demonstrate a less aggressive phenotype and a 
diminished attachment to laminin, an important part of metastasis (Givant-
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Horwitz et al. 2004). In this study by Givant-Horwitz et ai, human melanoma 
cells expressing reduced levels of 67 kDa LR showed increased 
phosphorylation of ERKl/2, JNK and p38 MAPK, and this was accompanied 
by a significant reduction of the mRNA of the enzyme MKP-l, which 
dephosphorylates ERK1!2, JNK and p38 MAPK. This suggests that a 67 kDa 
LR-related signal transduction pathway, which is associated with the MAPK 
pathway, does exist and suggests a potential mechanism for EGCG-mediated 
MAPK modulation. 
1.5.5 Anti-Obesity Effects (in vivo studies) 
Green tea has been regarded for centuries to possess significant health 
promoting effects, and was traditionally used to improve blood flow, eliminate 
alcohol and toxins, improve resistance to disease, relieve joint pain, to clear 
urine and improve its flow (Balentine et al. 1997). In recent years, research 
has focused on the anti-cancer, -cardiovascular disease and -obesity effects. 
EGCG is believed to be the active constituent of green tea, and studies have 
been carried out using intraperitoneal and intravenous administration, and 
dietary supplementation of pure EGCG, a mixture of green tea catechins, and 
ordinary green tea. A number of studies have been carried out in mice, rats and 
humans and all show that EGCG/green tea extract/green tea is able to reduce 
body weight and other obesogenic factors, even when subjects are on a high fat 
diet. 
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Intraperitoneal injection of 85 mglkg EGCG was injected into lean and obese 
Zucker rats and significantly reduced food intake, body weight, blood levels of 
leptin, resistin, insulin, insulin-like growth factor I, glucose, cho lestero I and 
triglyceride (Kao et at. 2000). Dietary supplementation using TEAVIGOHI. an 
extract from green tea which contains more than 94% EGCG but less than 
0.1 % caffeine, prevented the increase in body weight and adipose tissue mass 
induced by feeding a high-fat diet to C57BL/6J mice. This was accompanied 
by reduced expression ofFAS and acetyl-coenzyme A carboxylase-l mRNA in 
adipose tissue, suggesting that EGCG reduces lipogenesis in adipose tissue. In 
obese Sprague-Dawley rats, dietary supplementation resulted in a significant 
weight loss within 4 weeks (Wolfram et al. 2005). Another study using dietary 
supplementation with TEA VIGOTM in diet-induced obese New Zealand black 
mice resulted in a dose-dependent attenuation of body fat accumulation. 
Leptin gene expression in white adipose tissue was also reduced. Acute oral 
administration over 3 days had no effect on body temperature, activity and 
energy expenditure, whereas the respiratory quotient during their activity 
period was decreased, suggesting that EGCG decreased lipogenesis and 
increased fat oxidation. Food intake was not altered (Klaus et al. 2005). The 
effects of green tea extract on the endurance capacity, energy metabolism and 
fat oxidation in BALB/c mice was investigated over a 10 week period. Mice 
had increased swimming time to exhaustion after being fed green tea extract, 
they also had higher rates of fat oxidation and increased ~ - o x i d a t i o n n activity in 
skeletal muscle. Supplementation with TEA VIGOTM also enhanced endurance 
capacity in the mice. Food intake was not significantly different between the 
groups (Murase et at. 2005). Another study by the same authors compared the 
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effects of diets containing low fat, high fat or high fat supplemented with tea 
catechins on C57BL/6J mice over an 11 month period. The tea catechin 
supplementation resulted in a significant reduction of high-fat diet-induced 
body weight gain, visceral and liver fat accumulation, and the development of 
hyperinsulinaemia and hyperleptinaemia. No mention is made of food intake 
measurements in this study (Murase et al. 2006). In a study investigating the 
effect of powdered green tea in Zucker rats fed a 500/0 sucrose diet containing 
15% butter, it was found that green tea significantly attenuated body weight 
gain and decreased adipose tissue mass, while food intake was not affected 
(Hasegawa et al. 2003). 3 weeks of green tea drinking by Wistar rats 
significantly reduced adipose tissue weight compared to water drinking 
controls, however body weight was not affected. Plasma levels of free fatty 
acids and of total cholesterol were reduced and the LDLIHDL ratio was also 
decreased. Additionally, skeletal muscle glucose uptake was significantly 
increased and adipose tissue glucose uptake was significantly decreased. Food 
intake was unaffected. Furthermore, PP ARy expression was decreased in 
adipose tissue (Ashida et al. 2004). In mice fed a high fat diet, who were 
supplemented with EGCG (3.2 g/kg diet), corresponding to 10 cups (200 ml) of 
green tea (containing 2 g leaves per cup) per day, for 16 weeks, reduced body 
weight gain, percentage body fat and visceral fat weight compared with mice 
without EGCG treatment (Bose et ai. 2008). 
A study by Nagao et aI, where obese adults ingested green tea containing either 
583 mg or 96 mg catechins per day, for 12 weeks, revealed that decreases in 
body weight, body mass index, body fat ratio, body fat mass, waist 
circumference. hip circumference, visceral fat area, and subcutaneous fat area 
31 
Introduction 
were greater in the high catechin group (Nagao et al. 2007). A further study by 
the same authors was carried out on patients with Type 2 diabetes who were 
not receiving insulin therapy. Patients who ingested green tea containing 583 
mg catechins per day had a significantly decreased waist circumference after 
12 weeks compared to those who ingested only 96 mg catechins per day. 
Additionally, adiponectin levels were increased in the high catechin group 
(Nagao et al. 2009). Food intake measurements were not taken in either study. 
1.5.6 Anti-Obesity Effects (in vitro studies) 
Relatively little is known about the underlying mechanisms of the actions of 
the anti-obesity effects of flavanols but molecular and cellular studies have 
revealed that they are able to increase lipolytic activity, decrease lipogenic 
activity, increase fat oxidation and thermogenesis, and modulate the activity 
and expression of lipoproteins. More relevant to these studies, flavanols are 
also able to decrease cell numbers and decrease hormone stimulated 
proliferation of preadipocytes and their differentiation into adipocytes (Kao et 
al.2006). 
As previously mentioned, EGCG has an ERK1I2-dependent antimitogenic 
effect on preadipocytes, indicated by decreased cell number and decreased 
incorporation of bromodeoxyuridine in dose-, time-, catechin-, and growth 
phase dependent manners (Hung et al. 2005). Gallated catechins, especially 
EGCG are more active than other catechins, suggesting that EGCG may act 
differently from EC, EGC and EeG in regulating preadipocyte growth. EGCG 
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contains the largest number of hydroxyl groups on its three aromatic rings 
among the tea catechins, and these hydroxyl groups may be important for 
hydrogen bonding with other molecules. EGCG has both gallyl and galloyl 
groups which have some conformational flexibility, that may also be important 
for interactions with other molecules. 
Adipocyte differentiation is tightly regulated by several transcription factors, it 
is initiated by C / E B P ~ ~ and CIEBP8, which act together to induce PP ARy2, a 
key regulator for adipogenesis, and C/EBPa. CIEBPa and PP ARy together 
promote adipocyte differentiation by activating expression of adipose-specific 
genes and are also crucial for maintenance of each other's expression at high 
levels. CG and EGC at 30 /lM and EGCG at 10 and 30 /lM significantly 
down-regulate expression of PP ARy2 and C/EBPa during adipocyte 
differentiation (Furuyashiki et al. 2004). There is some evidence to suggest 
that PP ARy activity is inhibited by phosphorylation by activated ERK1I2 (Hu 
et al. 1996; Adams et al. 1997; Camp and Tafuri 1997; Reginato et al. 1998; 
Chan et al. 2001), suggesting that the anti-adipogenic effects of green tea 
catechins may be mediated, at least in part, via the ERK1I2 inhibition of 
PPARy and C/EBPa. 
A decrease in preadipocyte number can either be due to inhibition of 
mitogenesis, or induction of apoptosis. Using concentrations of EGCG below 
50 /lM, the cell viability of day 3 preadipocytes remained at 90-1000/0 during 
the 48hr treatment, whereas EGCG at doses of 100-400 /lM reduced the cell 
viability of preadipocytes by 15-30%, induced the appearance of DNA 
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fragmentation, and increased the activity of the caspase-3 protein, an apoptotic 
enzyme (Wu et al. 2005). 
There is evidence to suggest that flavanols are able to modulate the 
differentiation of adipocytes, another mechanism behind the potential anti-
obesity effects that flavanols have. A study by Kao et al (2000) revealed that 
10 JlM EGCG was able to inhibit preadipocyte proliferation by 50% and inhibit 
insulin-induced increases in cell number by 34% and the triacylglycerol 
content by 540/0 during a 9 day period of differentiation. Even in the presence 
of the prodifferentiative agents dexamethasone, IBMX and insulin, 10-100 JlM 
EGCG was also to reduce cell number and triacylglycerol content (Kao et al. 
2000). This suggests, therefore, that the in vitro effect ofEGCG on adipocytes 
may be mediated by modulation of hormone stimulated cell proliferation and 
differentiation. Additionally, it was shown that EGCG reduces the levels of 
adipogenesis-related transcription factors such as C I E B P ~ ~ and PP ARy, in 
differentiating 3T3-L1 preadipocytes treated with dexamethasone, IBMX and 
insulin (Kao et al. 2006). The study mentioned earlier by Furuyashiki et al 
(2004) showed that 10-30 JlM EGCG decreased lipid accumulation by 25-500/0 
in differentiating 3T3-L1 adipocytes (Furuyashiki et al. 2004). Another study 
has shown that 50-200 JlM EGCG could reduce the size and number of lipid 
droplets in differentiating 3T3-L1 adipocytes when it was added with the 
induction medium from days 0-6 of adipogenesis (Lin et al. 2005). 
The adipokine resistin is known to cause insulin resistance and decrease 
adipocyte differentiation (Steppan et al. 200 l) and has thus been proposed as a 
biomarker of insulin resistance and adipose tissue mass. It is possible that 
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EGCG exerts its effects through the modulation of resistin. In 3T3-L1 
adipocytes, EGCG suppressed resistin mRNA and protein in a time and dose-
dependent manner, via an ERK1I2 dependent pathway, as levels of pERK1/2 
were also reduced (Liu et al. 2006). 
1.6 Glucose Uptake 
Glucose uptake into cells is dependent on the activity of glucose transporters 
(GLUTs) which are membrane spanning proteins. GLUT 1 is ubiquitously 
expressed and functions to maintain basal glucose uptake. GLUT 4 is 
expressed by muscle and fat cells, and under basal conditions is sequestered in 
an intracellular compartment, however following stimulation by insulin, moves 
to the cell surface (Bryant et al. 2002). The major physiological action of 
insulin is to promote glucose uptake into muscle and adipose tissue by 
triggering GLUT4 translocation. It is defects in this system that contribute to 
the development of insulin resistance in Type 2 diabetes and obesity, as it is 
primarily the presence of GLUT4 in the plasma membrane that determines 
glucose utilisation in these tissues (Kahn 1996). Upon binding of insulin to its 
receptor, there is a net shift in the subcellular distribution of GLUT4 to the 
plasma membrane (Bryant et al. 2002). Once in the plasma membrane, 
GLUT4 facilitates diffusion of glucose into the cell, resulting in a 20-30 fold 
increase in the rate of glucose uptake in the presence of insulin. The effect of 
insulin on GLUT4 trafficking IS mediated, at least in part by 
phosphatidylinositol-3-kinase (PI-3 kinase), but the downstream effectors of 
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this enzyme, as well as the subcellular compartments that are mobilised, are 
poorly defmed (Watson and Pessin 2001). It is unclear whether the insulin-
stimulatable GLUT4 compartment is part of a regulated pathway for protein 
secretion. GLUT4 is present in the trans Golgi network, the site where most 
secretory vesicles form (Huang and Czech 2007). There is evidence to suggest 
that ERK1I2 activation up-regulates GLUTl expression resulting in increased 
basal uptake in the absence of insulin (Fingar and Birnbaum 1994; Fujishiro et 
al.2003). 
There are reports in the literature that suggest that flavonoids are able to 
modulate both basal and insulin-mediated glucose uptake. Kaempferol and 
quercetin, flavonoids extracted from Euonymus alatus, significantly improved 
imsulin-mediated glucose uptake when added to differentiated 3T3-Ll 
adipocytes at 5-50 /-LM for 3 days (Fang et al. 2008). The addition of (-)-
catechin to differentiated 3T3-Ll adipocytes at 50 /-LM for 24 hours also 
increased insulin-mediated glucose uptake (Cho et al. 2007). 
Berberine, an isoquinoline alkaloid, isolated from Chinese medicinal herbs 
such as Coptidis rhizoma and Cortex phellodendri, enhanced J:>asal glucose 
uptake in normal and insulin-resistant 3T3-Ll adipocytes when added at 5 /-LM 
for 6 hours (Kim et al. 2007). This study also demonstrated that berberine 
increased expression of GLUT-l but not GLUT-4 in 3T3-Ll adipocytes and 
that this was through an AMP-activated protein kinase and ERK mediated 
mechanism. The ERK1I2 pathway has been demonstrated to playa role in 
glucose transport, through treatment of 3T3-Ll adipocytes with the MEK 
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inhibitors PD98059 and U0126, which both inhibited insulin-mediated glucose 
uptake (Harmon et al. 2004). 
In comparison to the studies by Cho et aI, Fang et al and Kim et aI, 
investigation of genestein, an isoflavone derivative, showed significant 
inhibition of insulin-mediated glucose uptake when incubated at 50 ~ M , , 15 
min prior to insulin treatment in 3T3-L1 adipocytes (Bazuine et al. 2005). In 
isolated rat adipocytes, myricetin, quercetin and catechin-gallate showed 
significant inhibition of insulin-mediated glucose uptake when incubated in the 
range of 10-100 ~ M M (Strobel et al. 2005). Interestingly, in this same study, 
catechin had no effect on glucose uptake. 
Studies in vivo, in which rats have been given green tea instead of drinking 
water, for 3 (Ashida et al. 2004) or 12 weeks (Wu et al. 2004), have 
investigated the effects of flavonoids on glucose uptake. The study by Ashida 
et al showed that green tea significantly reduced glucose uptake, accompanied 
by a decrease in translocation of GLUT4 in adipose tissue, while it 
significantly stimulated glucose uptake with GLUT 4 in skeletal muscle. 
However, Wu et al reported that basal glucose uptake was significantly higher 
in rats in the green tea group, versus rats who had been drinking water. 
Evidence to date, on the effects of flavonoids on basal and insulin-mediated 
glucose uptake, suggests that the different flavonoids vary in their modulation 
of this process. As the characteristic of insulin resistance is the decrease of 
insulin sensitivity and glucose uptake in peripheral tissues, there is a possibility 
that certain flavonoids may be able to ameliorate insulin resistance. 
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1.7 Summary 
In summary, it appears that the green tea and cocoa flavanols have the potential 
to exert anti-obesity effects and there is already a wealth of literature 
suggesting that they are able to modulate weight gain and other obesogenic 
factors such as lipogenesis, ~ - o x i d a t i o n n and adipokine release. There is also 
evidence that the flavanols are able to modulate signalling pathways in 
adipocytes and preadipocytes but as yet defmite links between the signalling 
pathways and physiological outcomes have not been established. Key features 
of obesity and associated insulin resistance are adipokine dysregulation, 
decreased sensitivity of adipocytes to insulin and subsequently changes in 
glucose uptake by cells. The aims of this thesis were therefore to fIrstly 
establish an efficient system of differentiated adipocytes and secondly to use 
this to investigate the effects of the flavanols on physiological outcomes such 
as adipokine release and glucose uptake. Thirdly, the question of whether 
these processes might be regulated by the ERK1I2 pathway and what may be 
happening upstream of this was explored. Finally, the effect of flavanol 
treatment on adipocyte gene expression of genes known to be modulated in 
obesity was investigated. 
Materials & ~ f e t h o d s s
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2 Materials & Methods 
All materials were obtained from Sigma (Poole, UK) unless otherwise stated. 
2.1 3T3-Ll Cell Culture 
2.1.1 Materials 
FCS (foetal calf serum) and NCS (newborn calf serum) were obtained from 
P AA Laboratories (Somerset, UK). 
6 well plates were supplied by Corning Ltd (Sunderland, UK), Nalge Ltd 
(Hereford, UK), Orange Scientific (Belgium), Becton, Dickinson, Falcon 
(Oxford, UK), Iwaki, Asahi Techno Glass Corporation (Tokyo, Japan). Tissue 
culture flasks were supplied by Sarstedt Ltd. 35mm dishes, 12 and 24 well 
plates were supplied by Nalge Ltd. 
Oil Red 0 stain was obtained from British Drug Houses Ltd (Poole, England). 
3T3-L1 preadipocytes were obtained from American Type Culture Collection 
(ATCC). 
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2.1.2 Solutions 
Medium 1: Du1becco's Modified Eagle Medium (DMEM) high glucose with 
10% NCS, supplemented with 2mM glutamine, 1 % antibiotic/antimycotic mix 
and 0.5% gentamicin. 
Medium 2: DMEM high glucose with 100/0 FCS, supplemented with 2mM 
glutamine, 10/0 antibiotic/antimycotic mix and 0.5% gentamicin and containing 
0.5 mM 1-methyl-3-isobutylxanthine, 0.25 ~ M M dexamethasone and 166 nM 
insulin. 
Medium 3: DMEM high glucose with 100/0 FCS, supplemented with 2mM 
glutamine, 1 % 100X antibiotic/antimycotic mix (10000 D/ml penicillin G, 10 
mg/ml streptomycin, 25 ~ g / m l l amphotericin B) and 0.5% 10mgiml gentamicin 
and containing 166 nM insulin. 
Medium 4: DMEM high glucose with 10% FCS, supplemented with 2mM 
glutamine, 1 % antibiotic/antimycotic mix and 0.5% gentamicin. 
Oil red 0 stain: 1 % Oil red 0 in isopropanol, diluted 3:2 in PBS. 
2.1.3 Cell Culture 
Cells were seeded at either 5 x 104 cells/T75 flask, or 1 x 105 cells/35mm well 
and grown to confluence in medium 1. 48 hr after reaching confluence, 
differentiation was induced by incubation in medium 2 for 48 h. This start of 
differentiation was represented as post induction day 0 (PID 0). Cells were 
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then incubated in medium 3 for 48 h. Differentiated cells were maintained in 
medium 4 until needed for treatment (see Figure 2.1). Cells were grown at 
37°C, 50/0 humidity and 10% CO2 . 
PID 0 
PID 2 
PID 4 
PID 6 
Seed Cells in FlaskfWells in Medium 1 
Allow c eUs to 
be come tightly 
confluent for 
48hr 
Start Differentiation with Medium 2 
48hr 
Replac e with Medium 3 
48hr 
Replac e with Medium 4 
48hr 
Replac e with T re atment Medium 
C oUe ct I \ . ~ ~ e diafC e Us 
Figure 2.1 Diagrammatic overvieH' of 3T3-L1 differentiation protocol. 
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2.1.4 Oil Red 0 Staining 
Cells were stained using Oil Red 0 to determine whether the lipid content of 
cells had increased, and were therefore differentiated adipocytes. Following 
media removal, cells were washed three times with PBS and fIxed with 10% 
formalin solution at room temperature, for 10 minutes. Cells were then washed 
thrice with PBS and stained with Oil Red 0 for 1 hr at room temperature. 
Cells were then washed thrice with PBS, and fresh PBS was added to cover the 
cell surface and prevent dehydration. 
2.2 ELISA 
2.2.1 Materials 
Mouse Adiponectin Duoset and Resistin Duoset ELISA kits were obtained 
from R&D Systems Europe Ltd (Abingdon, UK). 
2.2.2 Method 
Collected media samples were assayed for mouse adiponectin and mouse 
resistin using ELISA duosets in 96 well plates. Initially, samples were assayed 
at a range of dilutions, in order to determine the optimum dilution for 
adipokine measurement. Finally, samples assayed for adiponectin and resist in 
were diluted 1: 100. All samples and standards were prepared and assayed in 
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triplicate. Wavelength of 96 well plates was measured and analysed using 
Dynex Revelation 4.22 (Dyne x Technologies Ltd, Worthing, UK). 
2.3 Western Blotting 
2.3.1 Materials 
Complete Protease Inhibitor Complex was supplied by Roche (West Sussex, 
UK). BCA Protein Assay Reagent was supplied by Pierce (Thermo Fisher 
Scientific Inc, Illinois, USA). Mini Protean 3 system was supplied by BioRad 
(Hemel Hempstead, UK). 30% Bis-Acrylamide was supplied by Severn 
Biotech (Kidderminster, UK). PageRuler Pre stained Protein Ladder Plus was 
supplied by Fermentas (York, UK). Nitrocellulose membrane, ECL reagents 
and photographic film were supplied by GE Healthcare (Amersham, UK). 
Developing and Fixing solutions were supplied by Kodak (Hemel Hempstead, 
UK). 
Antibodies 
Anti-cyclophilin B was supplied by Abcam (Cambridge, UK). Anti ERK. 
pERK and PPARy antibodies were supplied by Cell Signaling Technology 
(New England Biolabs, Hitchin, UK). Anti-Dok-l antibody was supplied by 
Santa Cruz (California, USA). Swine anti-rabbit and goat anti-mouse 
secondary antibodies were supplied by Dako (Ely, UK). 680 anti-rabbit 680 
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anti-mouse, 800 anti-rabbit and 800 anti-mouse secondary antibodies were 
supplied by Li-Cor Biosciences (Cambridge, UK). 
2.3.2 Solutions 
Phosphate Protective Lysis Buffer 
50mM HEPES, 10% (v/v) glyceroL 1mM EDTA, 10mM NaF, activated* 1mM 
Na3V04, 150 mM NaCl, 1% (v/v) triton X-100, pH 7.5, supplemented with 
Complete Protease Inhibitor Cocktail (1 tabletll 0 mllysis buffer). 
*activation process for Na3 V04: 200mM Na3 V04 was dissolved in HPLC 
purified water, and adjusted to pH lOusing HCl. This solution was activated 
by boiling until the solution changed from yellow to colourless, cooled to room 
temperature and the pH readjusted to 10. This was repeated before finally 
being stored at -20°C. Activation depolymerises the vanadate converting it to 
a more potent inhibitor of protein tyrosine phosphatises. 
4x Sample Buffer 
0.250M Tris, 40% v/v glycerol, 4% w/v sodium dodecyl sulphate (SDS), 20% 
v/v B-mercaptoethanol and 0.002% bromophenol blue. 
Lowry Reagents 
A: 0.1 M NaOH containing 2% (w/v) Na2C03, 20/0 (w/v) NaK tartrate. 10/0 
CuS04*5H20. 
B: 10% Folin-Ciocalteu phenol in 0.1 M NaOH. 
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Electrophoresis Buffer 
25mM Tris, 192mM glycine, 3rnM SDS. 
Transfer Buffer 
25mM Tris, 192mM glycine 20% v/v methanol. 
Tris Buffered Saline with Tween (TBS-T) 
25mM Tris, 125mM NaCl, 0.1 % v/v Tween 20 pH 7.6. 
Blocking Buffer/Antibody Buffer 
5% (w/v) skimmed milk powder in TBS-T. 
2.3.3 Sample Preparation Using Phosphate Protective Lysis 
Buffer 
Medium was aspirated from cells and cells were given 3 x PBS washes before 
being harvested in 1.5ml PBS. This cell suspension was centrifuged at 
6000rpm for 5 min at 4°C to pellet the cells. The PBS supernatant was 
removed, 150 JlI lysis buffer was added per well and the cells lysed by 
sonication. Finally, the cell lysate was centrifuged at 10000rpm for 5 min at 
4°C. 20 JlI of lysate was aliquoted to measure protein concentration using the 
Lowry assay and 43 JlI of 4X sample buffer was added to the remaining 130 JlI 
of cell lysate for Western blotting. 
46 
i.lIaterials & 1 ~ I e t h o d s s
2.3.4 Sample Preparation Using TriReagent 
Culture medium was aspirated from cells and cells were given a PBS wash 
before being harvested in 1 ml TriReagent and incubated at room temperature 
for 5 min. 0.2 m11-bromo-3-chloropropane was added to this cell suspension, 
which was vortexed and centrifuged at 10000 rpm for 10 min at 4°C to separate 
into aqueous phase, interphase and organic phase containing RNA, DNA and 
protein respectively. The aqueous phase was removed for RNA isolation, 
interphase discarded and 950 III isopropanol added to the organic phase to 
precipitate the protein. Following vortexing, this homogeneous solution was 
centrifuged at 5000 rpm for 10 min at 4°C. The supernatant was discarded and 
the protein pellet was washed with 0.3M guanidine hydrochloride in 95% 
ethanol and centrifuged at 7200 rpm for 5 min at 4°C, this wash and 
centrifugation was repeated a further 2 times. Following removal of the fmal 
wash, 1 ml 100% ethanol was added to the pellet and incubated at room 
temperature for 20 min. Following centrifugation at 7500 rpm for 10 min at 
4°C, the supernatant was removed and 100 III 1 % SDS, 7M urea buffer added, 
samples were sonicated, followed by boiling at 99°C for 10 min to aid 
solubilisation. 
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2.3.5 Protein Determination 
2.3.5.1 Lowry Assay 
In a 96 well microassay plate, bovine serum albumin (BSA) (1 mg Iml) was 
diluted with O.lM NaOH in a volume up to 200 ~ l l to achieve a series of protein 
concentrations 5-80 ~ g g to be used as standards, in duplicate. 200 III of O.lM 
NaOH in duplicate was used as blank. 5 ~ l l of protein extracted was made up to 
200 ~ l l with O.1M NaOH and used for the assay in duplicate. 50 ~ l l of reagent A 
was added to each well and incubated for 5 minutes at room temperature, 
followed by adding 50 ~ l l of reagent B to each well and left for at least 15 
minutes at room temperature. The absorbance of protein samples and standard 
BSA was measured at a wavelength of630 nm. 
Following calculation of the protein levels, all sample protein levels were 
normalised to 2 ~ g / ~ 1 1 using a 1:3 mixture of 4X sample buffer and lysis buffer 
and stored at -20oe. 
2.3.5.2 BCA Protein Assay 
Protein determination was carried out according to manufacturer's instructions, 
using 1 ~ l l sample per assay. 
~ ~ ~ - ~ - - - - ~ ~---
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2.3.6 Electrophoresis 
Samples were defrosted, heated to 95°C for 5 minutes, mixed briefly and spun 
in a microcentrifuge for 1 minute. Samples, of 50 flg protein each were then 
loaded on to 16% polyacrylamide gels for electrophoresis. PageRuler 
Prestained Protein Ladder Plus, a standard of marker proteins of known 
molecular weight, was run alongside the samples to show the distance travelled 
by protein of each weight. An internal control, made up of a pool of all 
samples was run on each gel such that a comparison could be made between 
gels as well as within each gel. Gels to be processed using the ECL system 
were run in duplicate, such that the total and phosphorylated forms of proteins 
could be detected, avoiding the need for stripping antibodies from membranes 
and re-incubating with antibodies. Gels to be processed using the Odyssey 
system were not run in duplicate as different secondary antibodies, that were 
visible at different wavelengths were bound to the total and phosphorylated 
forms, such that both forms could be visualised on the same gel and could be 
differentiated between. The gels were run in electrophoresis buffer at room 
temperature. Samples were separated for approximately 90 minutes at 100V 
using BioRad MiniProtean III equipment. 
Once the sample proteins had been separated they were transferred onto a 
nitrocellulose membrane in transfer buffer, for 65 min at 105V, also using 
BioRad Mini Protean III equipment. 
The nitrocellulose membrane was then stained with Ponceau S solution \vhich 
stains all protein pink. This step is a quick check to ensure the running and 
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transfer steps have worked correctly as a band of protein should be clearly 
visible on the membrane. The Ponceau stain was washed off the membrane 
using water and TBS-T. 
2.3.7 Blotting 
The non-specific binding on the membranes was blocked usmg blocking 
buffer, gently agitated for 1 hour at room temperature. The lower half of the 
membrane, which contained the low molecular weight proteins, was then 
incubated with 1 :500 dilution of anti-cyclophilin B. Cyclophilin B is used as a 
non-variant control protein to ensure slight differences in protein loading can 
be corrected for (Sinha et al. 2005). The upper half of each membrane was 
incubated with antibodies to ERK, pERK, Dok-l, PP ARy and pPP ARy at the 
dilutions shown in Table 2.1 and Table 2.2. All antibodies were diluted in 
antibody buffer. The membranes and antibody so lutions were incubated 
overnight at 4°C in 50 ml centrifuge tubes on a roller. 
Table 2.1 Details a/primary and secondary antibodies used with EeL 
Cyclophilin ERK pERK 
Approx; weight (kDa) 21 42/44 42/44 
Primary antibody Abcam Cell Signaling Cell Signaling 
ab3565 #9107 #9106 
1:500 1:250 1:250 
Secondary antibody Dako Swine Dako Goat Anti- Dako Goat Anti-
Anti- Rabbit Mouse Mouse 
P0217 P0447 P0447 
1 :2000 L ~ O O O O 1:2000 
Film exposure time 10 min Ihr Ihr 
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The following day the excess antibody was removed with 9 washes in TBS-T 
over a one hour period, at room temperature. For secondary antibodies to be 
used in conjunction with EeL (Table 2.1), these were added, again in antibody 
buffer, and incubated at room temperature for one hour, while shaking. These 
secondary antibodies were conjugated with horse radish peroxidase (HRP) 
which catalyses the enhanced chemical luminescence (EeL) reagents in a light 
emitting reaction. Following secondary antibody incubation the membranes 
were again washed 9 times over one hour, with a [mal wash in water. The 
membranes were then incubated with the EeL reagents (Amersham, UK), as 
per manufacturer's directions, and exposed to autoradiography film (Kodak, 
UK). 
Table 2.2 Details of primary and secondary antibodies used with Odyssey 
system 
Cyc10philin ERK pERK 
Approx. weight (kDa) 
21 42/44 42/44 
Primary antibody Abeam Cell Signaling Cell Signaling 
ab3565 #9107 #4370 
1:250 1:250 
1:500 
Secondary Antibody Odyssey 680 Odyssey 680 Odyssey 800 
Anti-Rabbit Anti Mouse Anti Rabbit 
1:10000 1 :10000 1:10000 
For secondary antibodies to be used in conjunction with the Odyssey system 
(Table 2.2), these were added, again in antibody buffer, and incubated in the 
dark, at room temperature for one hour, while shaking. Following secondary 
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antibody incubation the membranes were again washed 9 times over one hour. 
with a fmal wash in water. Protein bands were then visualised using the 
Odyssey scanner and software. 
2.3.8 Determination of Density of Protein Bands 
The density of the protein bands visualised by EeL was determined using a 
densitometer (BioRad, UK) and the manufacturer's software, Quantity One. 
The density of the protein bands visualised by the Odyssey system was 
determined using Odyssey software. To account for variations between gels, 
an internal control, constituting small volumes of each sample pooled together, 
was loaded onto each gel, and the cyclophilin B bands normalised to this, 
before being used to normalise all other protein bands. All densities were then 
expressed as a percentage of the mean vehicle control density for that sample 
group. 
2.3.9 Statistical Analysis 
Data were analysed with a one way ANOV A and Tukey post hoc test, using 
GraphPad Prism, version 4.02 (GraphPad Software Inc). 
2.4 GTPyS Binding Assay 
52 
Materials & JJethods 
2.4.1 Materials 
Human Embryonic Kidney (HEK) cells expressmg rat recombinant CB2 
receptors obtained from Dr Mary E Abood (Temple University, Philadelphia) 
were grown to confluence by Mauro Dionisi. [35S]GTPy was purchased from 
GE Life Sciences (Bucks, UK). 
2.4.2 Solutions 
Assay buffer: 50 mM Tris-HCI, 9 mM MgCh, 0.2 mM EGTA, 150 mM NaC1, 
pH 7.4. 
Wash buffer: 50 mM Tris-HCI, 5 mM MgCh, pH 7.4. 
2.4.3 Method 
HEK cells were grown to confluence and harvested using PBS containing 
EDTA. Cells were centrifuged at 25,000 rpm for 10 min at 4°C to separate all 
cell organelle membranes. The pellet was then resuspended in assay buffer, 
homogenised, and centrifuged as previously. The [mal pellet was then 
resuspended in assay buffer, homogenised, and diluted to a concentration of 2 
Jlg/JlI with assay buffer. 
10 Jlg of homogenised HEK cell membranes were incubated in assay buffer, 
containing 0.1 % BSA with GDP 100 JlM, [35S]GTPy S 0.05 nM. and catechin, 
epicatechin or EGCG at 10 JlM and 1 JlM HU210, a CB, agonist in siliconiscd 
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glass tubes. The total assay volume was 0.5 ml, which was incubated for 90 
min at 30°C in a shaking water bath. The reaction was terminated by the 
addition of 2 ml ice-cold wash buffer, followed by rapid filtration under 
vacuum through Whatman GF/C glass-fibre filters, washing with 2 x 3ml ice-
cold wash buffer. Filters were transferred to 5 ml scintillation vials. Bound 
radioactivity was determined by liquid scintillation spectrophotometry after 
extraction in 3 ml scintillant overnight at room temperature. Non-specific 
binding was determined using 10 /-lM GTPyS. Basal binding was assayed in 
the absence of flavanol and in the presence of GDP. The stimulation by 
flavanol was defmed as a percentage increase above basal levels (i.e., [dpm 
(flavanol)-dpm (no flavanol)] x 100). 
2.5 2-Deoxyglucose Uptake Assay 
2.5.1 Materials 
[3H] 2-DOG was purchased from GE Life Sciences (Bucks, UK). 
2.5.2 Solutions 
Reaction Buffer: 138 mM NaCl, 1.85 mM CaCh, 1.3 mM MgSO.+, 4.8 mM 
KCL, 0.2% w/v BSA, 50 mM HEPES pH 7.4. 
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2.5.3 Method 
3T3-Ll cells were seeded at 6 x 104 cells/well in 12 well plates, induced to 
differentiate once confluent, and maintained in medium 4. 24 hours prior to 
the start of the assay, medium was replaced with 12.5 mM glucose DMEM, 
followed by overnight serum starvation in 12.5 mM glucose medium. Cells 
were washed three times with PBS at 37°C and incubated with 1 ml reaction 
buffer (section 2.2.5) for 45 minutes. Cells were treated with 250 JlI 
cytochalasin B for 10 minutes or EGCG/epicatechin for 30 min, 6 hr and 24 hr. 
500 JlI insulin (0.1 JlM) was added or not, for 10 minutes, followed by the 
addition of 250JlI of 27.8kBq eH] 2-DOG and 1.5mM 2-DOG for 10 min. 
Cells were then washed with ice cold PBS containing 10mM glucose (3x) and 
solubilised in 500Jll 0.5M NaOH and 0.1 % SDS. Cell lysate was transferred to 
scintillation vials and 5mlliquid scintillant was added. Samples were assayed 
for 2-DOG uptake as disintegrations/min/well using a Rackbeta liquid 
scintillation counter (LKB Instruments, Maryland, USA). 
2.6 Gene Expression Studies 
2.6.1 Materials 
RNeasy Mini Total RNA Purification Kits were supplied by Qiagen (West 
Sussex, UK). Reagents for Reverse Transcription of RNA to cDNA were 
supplied by Invitrogen (Paisley, UK). TaqMan reagents were supplied by 
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Applied Biosystems (CA, USA). Primers and probes were supplied by 
Eurofms MWG GmBH (Ebersberg, Germany). 
2.6.2 RNA and Protein Extraction 
Cells were collected in 1 ml TriReagent and protein and RNA were 
simultaneously extracted (Sambrook et al. 2001). 
2.6.3 Purification of RNA 
Total RNA was further purified using the RNeasy Mini Total RNA Purification 
Kit according to the manufacturer's protocol, including an on column DNase 
digestion. Total RNA was quantified using absorption at 260 nm using a 
NanoDrop ® ND-I000 spectrophotometer. Total RNA was stored at -80°C 
until required. 
2.6.4 Reverse Transcription of Total RNA to cDNA 
The total RNA extracted from 3T3-Ll cells in Section 2.3.4 was reverse 
transcribed to cDNA using the reverse transcription reaction. Total RNA 
(500ng) was made up to a volume of 15 III with DEPC treated water and 1.5 III 
random primers (250 ng/Ill) and 1.5 III dNTP mix (10 mM) were added to 
make a total volume of 18 Ill. This was heated in a thermal cycler (Primus-96, 
MWG Biotech) and heated to 65°C for 5 min and kept on ice. Following a 
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brief centrifugation, a 1 0.5 ~ l l master mix was prepared and added to each 
sample, consisting of 6 ~ l l 5X First Strand Buffer, 3 ~ l l O.IM DTT and 1.5 ~ l l
Recombinant RNasin Ribonuclease Inhibitor (1 U / ~ l ) . . The mixture was 
incubated at 37°C for 2 min and 1.5 ~ l l M-MLV (Moloney Murine Leukaemia 
Virus) Reverse Transcriptase (200 U / ~ l ) ) added and mixed by pipetting gently. 
The mixture was then incubated at 37°C for a further 50 min and the reaction 
inactivated by heating at 70°C for 15 min. To remove RNA complementary to 
the cDNA, 1.5 ~ l l E.Coli RNase H (2 U / ~ l ) ) was added, and the reaction 
incubated at 37°C for 20 min. Following this, the mixture was diluted 1:4 with 
HPLC grade autoclaved water and stored at -20°C until required. 
2.6.5 Analysis of mRNA Expression by TaqMan® Quantitative 
Real Time peR 
TaqMan reagents use a fluorogenic probe to enable detection of a specific PCR 
product as it accumulates during PCR cycles, and works as follows (see Figure 
2.2). 
Step 1 - an oligonucleotide probe is constructed with a fluorescent reporter dye 
bound to the 5' end and a quencher at the 3' end. While the probe is intact, the 
proximity of the quencher greatly reduces the fluorescence emitted by the 
reporter dye by fluorescence resonance energy transfer (FRET) through space. 
Step 2 - if the target is present, the probe anneals between primer sites and is 
cleaved by the 5' nuclease activity ofTaq DNA polymerase during extension. 
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Cleavage of the probe separates the reporter dye from the quencher, increasing 
the reporter dye signaL and also removes the probe from the target strand, 
allowing primer extension to continue to the end of the template strand. Thus, 
inclusion of the probe does not inhibit the overall PCR process. 
Step 3- more reporter dye molecules are cleaved from their respective probes 
with each cycle, resulting in an increase in fluorescent intensity proportional to 
the quantity of amplicon produced. The higher the starting copy number of the 
nucleic acid target, the earlier a significant increase in fluorescence is 
observed. 
Polymerization 
FORWARD fA . tQ\ R : R E P O R T E ~ ~
5,_Pl'lI_ME_R ___ ~ ~ PROBE Y'3' Q:QUENCHER 
3'------------ 5' 
~ ~ Y 
---___ 5' 
REVERSE 
PRIMER 
Step 1: A reporter (R) and a 
quencher (0) are attached to the 
5' and 3' ends of a TaqMan 
probe. 
Cleavage 
5 . - - - - - ~ - - : : ~ - ~ ® y y3'------------ 5' 
5'------------3' __ ___ 5' 
Step 2: During each extension 
cycle, the AmpliTaq GolcJ® DNA 
polymerase cleaves the reporter 
dye from the probe. 
Strand Displacement 
5'-----.... ~ - - - - ® 3 ' '3'------------ 5' 
5' 3' 
_-___ 5' 
Step 1 (continued): When both dyes 
are attached to the probe, reporter 
dye emission is quenched. 
Polymerization Completed 
~ . . -.' .!!J3' , 5'-----------__ 3' ~ ~
5'------------3' 
------------- 5' 
Step 3: After being separated from 
the quencher, the reporter dye 
emits its characteristic 
fluorescence. 
Figure 2.2 Use of jluorogenic probe to enable detection of a specific peR 
product as it accumulates during peR cycles. 
(From Relative Quantification: Applied Biosystems 73001750017500 Fast Real-
Time peR System: Getting Started Guide: Rev D (Part #: 4347824)) 
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The probes used here for real-time peR are hydrolysis probes and have a 
fluorescent reporter (F AM) in close proximity to a quencher (T AMRA), which 
prevents the fluorescent reporter from emitting fluorescent signals. As the 
peR reaction progresses, the 5' nuclease activity of the polymerase cleaves the 
hydrolysis probe, releasing the fluorescent reporter from its quencher, resulting 
in an increase in fluorescence. 
peR amplification is characterised by three phases; lag, log-linear and plateau 
phases. In the lag phase, the increasing number of products remains below 
background fluorescence levels, until a critical point is reached where peR 
amplification reaches an exponential phase (log-linear) when 10 11 _10 12 peR 
product molecules are present. The reaction terminates when enzymes or other 
reaction components become limiting, also known as plateau phase. 
The greater the amount of the target gene present, the fewer the number of 
cycles required to reach the log amplification phase for a particular gene. 
Relative concentrations of mRNA can be determined by real-time peR from 
standards prepared by serial dilutions of cDNA, which can also be used to 
determine peR amplification efficiency. The most concentrated standard was 
prepared by combining 10 JlI aliquots from each cDNA reaction together and 
standards were prepared by serial dilutions (4, 16, 64, 256: 1 v/v) of the 
concentrated standard, which was given a concentration value of 1. 
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2.6.6 Primer and Probe Design for Real-time peR 
Primers and probes for PP ARy, adiponectin, resistin and leptin were designed 
using Primer Express® Software, version 3 (Applied Biosystems) Where 
possible, primer and probe sets were designed to cross intron-exon boundaries 
of the gene of interest to minimise risk of amplification from chromosomal 
DNA. Specificity of primers and probes were analysed (BLAST N) to ensure 
the gene of interest would be the primary target for amplification. Primers and 
probes were diluted to a 10 IlM working concentration and stored at -20°C (see 
Table 2.3 for details). TaqMan ® Gene Expression Assays were ordered for 
adipsin (complement factor D), FABP4, PEPCK, SREBF1, eukaryotic 18S 
RNA and beta actin, details of which can be found in Table 2.4 
Table 2.3 Oligonucleotide sequences ofprimers and probes used in RT-PCR. 
Primers and probes were designed using Primer Express® Software, version 3, 
blasted using http://www.ncbi.nih.gov and synthesised by Eurofins MWG 
GmbH. 
Gene Sequences (5'---+3') Amplicon GenBank 
size (bp) Accession No. 
PPARy FW: CCCTGGCAAAGCATTTGTAT 225 NM 001127330 
REV: GAAACTGGCACCCTTGAAAA 
PROBE: GGGCGATCTTGACAGGAAAGACAA 
Adiponectin FW: TGGATCTGACGACACCAAAA 157 NM 009605 
REV: ATCCAACCTGCACAAGTTCC 
PROBE: CCAGTCATGCCGAAGATGACGTTA 
Resistin FW: TCATTTCCCCTCCTTTTCCT 210 NM 022984 
REV: CAAGACTGCTGTGCCTTCTG 
PROBE: TCTTCCTTGTCCCTGAACTGCTGG 
Leptin FW: TGACACCAAAACCCTCATCA 213 NM 008493 
REV: TCATTGGCTATCTGCAGCAC 
PROBE: CACTGGCTTGGACTTCATTCCTGG 
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Table 2.4 TaqMan Inventoried Gene Expression Assays (Applied Biosystems) 
Gene Assay ID Arnplicon GenBank Accession ~ o . .
size (bp) 
FABP4 Mm00445878 m1 74 NM 024406 
Adipsin (complement factor D) Mm00442664 m 1 102 NM 013459 
PEPCK Mm01247058 m1 61 NM 011044 
SREBFl MmOI138344 ml 80 NM 011480 
Beta-actin Mm00607939 s 1 115 NM 007393 
Eukaryotic I8S ribosomal RNA Hs99999901 s I 187 X03205 
2.6.7 Real-time peR Assay 
A master mix for the target gene was made up for the number of wells required 
(see Table 2.5) 
Table 2.5 peR Master Mix components 
Volume per well (".11) 
TaqMan 2X Universal PCR Master Mix 13 
Forward Primer 0.75 
Reverse Primer 0.75 
Probe 0.5 
HPLC Water 5 
TOTAL 20 III per well 
AmpErase ® Uracil-N-Glycosylase (UNG) and AmpliTaq Gold ® DNA 
Polymerase are components of the TaqMan Universal PCR master mix. 
AmpErase UNG treatment can prevent the reamplification of carryover-PCR 
products by removing any uracil incorporated into single- or double-stranded 
DNA. AmpliTaq Gold DNA Polymerase ensures a robust reaction and 
dramatically reduces the amount of non-specific product formation. 
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20 JlI master mix and 5 JlI cDNA standard or unknown sample was added to 
each well, (all samples and standards were assayed in triplicate), sealed with 
optical transparent film and cycled as outlined in Table 2.6. 
Table 2.6 TaqMan cycle details 
Temperature Time Purpose 
50°C 2 min HOLD ArnpErase® UNG 
Activation 
95°C 10 min HOLD ArnpliTaq Gold® DNA 
Polymerase Activation 
95°C 15 sec Melt 
40 CYCLES 
60°C 1 min Ann eallE xt end 
The important parameter for quantification is the thresho ld cycle, or the Ct 
value. The Ct value is the cycle at which the fluorescent signal is first recorded 
as statistically significant above baseline and will always occur during the 
exponential phase of amplification of PCR product. The standard curve was 
generated by plotting the Ct values against the logarithm of the initial cDNA 
dilutions. Data from TaqMan was only used when the slope of the standard 
curve was -3.2 to -3.6 ( ~ ~ 100% efficiency) and when the Ct value for the 
triplicate readings for an individual sample were less than 0.5 Ct apart. 
p-actin and 18S ribosomal RNA were used as the non-variant normalising 
genes and all gene expression data were normalised to p-actin levels. 
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Adipokines: 
investigation of adiponectin and resistin 
release from 3T3-Ll adipocytes 
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3 Adipokines 
3.1 Introduction 
Adipose tissue is responsible for storage of excess energy as fat, and is able to 
release this as fatty acids and glycerol in periods of fasting and starvation. 
Adipose tissue is now being regarded as an endocrine organ, which is able to 
secrete a range ofbioactive polypeptides, known as adipokines. These include 
adiponectin, resistin, leptin, adipsin, visfatin, interleukin-6 (IL-6), tumour 
necrosis factor-a (TNFa) , serum amyloid A (SAA), plasminogen activator 
inhibitor-1 (P AI-I), angiotensinogen, vaspin and omentin. 
The 3T3-LI adipocyte cell model has been reported to secrete a number of 
adipokines into their media. This occurs under basal conditions and can also 
be regulated by the addition of insulin, growth factors and other agents (Hu et 
al. 1996; Kim et al. 2001). The first aim of this study was to set up a reliable 
cell culture system in which the release of the adipokines adiponectin and 
resistin from mature 3T3-L1 adipocytes could be measured, and secondly, 
investigate the release of these adipokines under the control offlavanols. 
3.2 Effect of tissue culture plate type 
While establishing 3T3-L1 cell culture conditions in six well plates in order to 
carry out these studies, disappointingly low differentiation efficiency was 
observed. These cells had not lost their ability to differentiate as good 
differentiation was seen when cells were plated in flasks. It was therefore 
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decided that the differentiation of these cells in different plate types would be 
examined. Information regarding plate type and brand used for 3T3-Ll studies 
in the literature has not been reported in detail. Significant differences in 
differentiation were observed between plates, and since efficient differentiation 
of these cells is crucial for their study, it is important that conditions providing 
the highest level of differentiation are used. 
Table 3.1 Suppliers of cell culture plates and dishes used 
Brand/Supplier Plate Description Catalogue 
Number 
Corning Costar ® 6 well, 35 mm, tissue culture treated, flat 3506 
(Coming Ltd. bottom, polystyrene microplates 
Sunderland, UK) 
Nunc10n ™ ~ ~ 6 well, 35 mm, flat bottom polystyrene 140685 
(Nalge Ltd. 
Hereford, UK) 
Orange Scientific Tissue culture 6 well test-plate, 35 mm 20030009 
(Orange Scientific. diameter, gamma sterilised, tissue culture 
Belgium) treated. 
Falcon ® 6 well, 35 mm diameter, Multiwell ™ 3846 
(Becton, Dickinson, tissue culture plate, 
Falcon. Oxford, UK) flat-bottom with low evaporation lid, 
surface-modified polystyrene. 
Falcon ® 6 well, 35 mm diameter, Multiwell ™ 3046 
(Becton, Dickinson, tissue culture plate, flat-bottom with low 
Falcon. Oxford, UK) evaporation lid, tissue culture treated by 
vacuum gas plasma. 
Iwaki 6 well, 35 mm diameter, TC-treated, flat 3810-006 
(I waki, Asahi bottom, polystyrene. 
Techno Glass 
Corporation. Tokyo, 
Japan) 
Sarstedt. Tissue culture 6-well plate, 35 mm 83.1839.300 
(Sarstedt Ltd. diameter, flat-bottom, Cell+ treated. 
Leicester, UK) 
Nunclon ™ ~ ~ 35 mm diameter dish, polystyrene 150318 
(Nalge Ltd. 
Hereford, UK) 
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Cells were seeded in plates and dishes (listed in Table 3.1) at 6 x 10-+ 
cells/35mm well and differentiated as detailed in Chapter 2. Once 
differentiated, medium was removed to fIx and stain the cells, as detailed in 
Section 2.1.4. 
Six 35 mm wells were seeded per plate in each plate used, alternatively cells 
were seeded into six 35mm dishes. Adipocytes and fIbroblasts in 3 
fIelds/35mm well were counted at x40 magnifIcation, and differentiation 
effIciency calculated as mean number of adipocytes as a percentage of total 
cells per well ± SEM. 
Cells were photographed at x40 magnifIcation under a light microscope using a 
Sony Cybershot 5.1-megapixe1 digital camera. 
3.2.1 Results 
The highest differentiation effIciency was observed in cells plated in Nunc10n 
T M ~ ~ 35 mm dishes, and the lowest differentiation efficiency was observed in 
cells plated in Corning Costar ® 6 well plates. Figure 3.2 shows a 
photographic comparison of cell differentiation in the two plate types. The 
differentiation effIciency seen in Nunc10n T M ~ ~ 35 mm dishes was signifIcantly 
higher than in any other plate brand used in this study (p<0.00 1) as shown in 
Figure 3.1. 
Corning Costar ® and Nunc10n T M ~ ~ 35 mm dishes were used in 2 more 
independent experiments. Differentiation efficiencies 25% ± 0.84 and 35% ± 
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0.83 (n=6, triplicate determinants) were observed for Corning Costar ® and 
67% ± 0.80 and 730/0 ± 1.1 5 (n=6, triplicate determinants) were observed for 
Nunclon T M ~ ~ 35 mm dishes (see Figure 3.3). 
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Figure 3.1 Effect of p late type on percentage differentiation of 3T3-L1 cells. 
Results are expressed as percentage of differentiated 3T3-L1s :t SEM, (n=6, 
triplicate determinants) . Statistical analysis was carried out using one-way 
ANOVA, and Tukey post-hoc test. *** p<O.OOl compared to all other plate 
brands. 
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Figure 3.2 Photographs of cells plated and differentiated on (a) Corning 
Costar ® and (b) Nunclon TM,j 35 mm dishes. 
Cells were fixed and stained with Oil Red O. Images were taken at x40 
magnification under a light microscope using a Sony Cybershot 5.1-megapixel 
digital camera. 
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Figure 3.3 Effect of plate type on percentage differentiation of 3 T3-Ll cells. 
Three independent experiments using Corning Costar ® and Nunclon™ L1 35 
mm dishes. Results are expressed as percentage of differentiated 3T3-Lls ± 
SEM, (n=6, triplicate determinants). Statistical analysis was carried out using 
one-way ANOVA, and Tukey post-hoc test. *** p<O.OOl compared to Corning 
Costar ®. 
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3.3 Measurement of Adipokines 
Following the development of a system in which 3T3-Ll fibroblasts were able 
to efficiently differentiate into mature adipocytes, the next stage of the study 
was to find and optimise a method for measurement of the secreted adipokines 
adiponectin and resistin. There are a number of kits to measure adipokines 
which are commercially available. The mouse adiponectin and resistin 
Duosets (R&D Systems Europe Ltd, Abingdon, UK) were chosen on the basis 
that they are specifically designed for the analysis of cell culture supernatants 
and are complete with protocols optimised for antibody concentrations and a 
protein standard which is mass calibrated to eliminate variation between assay 
kits. Standard curves for each adipokine had to be optimised, to ensure that all 
samples were falling within the middle of the range. Additionally, standard 
curves were constructed in medium, and blank medium was run as a control, 
instead of the suggested 1 % BSA in PBS. 
For validation of each assay, standard curves with R2 values less than 0.97 
were discounted, as were samples with replicates that were more than 2 
standard deviations out. Catechin, epicatechin and EGCG treated samples for 
each adipokine within each experiment were run at the same time, to ensure 
consistency and allow these samples to be compared. For each treatment and 
time point, 6 dishes were cultured (n=6) and duplicate determinants of each of 
these were assayed for adipokine release. 
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Figure 3.4 shows standard curves for adiponectin and resistin, resulting from 
use of R&D Systems' mouse adiponectin and resistin Duosets, representative 
of those used in these studies. 
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Figure 3.4 Representative standard curves for adiponectin (a) and resistin (b) 
from Duosets (R&D Systems) used for analysis of cell culture supernatant. 
Standard curves with R2 values of less than 0.97 were discounted from studies. 
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3.4 Effect of Flavanols 
In order to investigate the influence of dietary factors on adipokine release 
from 3T3-LI adipocytes, the effects of the green tea and cocoa flavanols, 
catechin, epicatechin and EGCG, were investigated. 
Cells were differentiated as detailed in Chapter 2, treated with varymg 
concentrations of catechin, epicatechin or EGCG for the required time, media 
removed and assayed for adiponectin or resistin using mouse adiponectin and 
resistin duoset ELISA kits. 
3.4.1 Preliminary Concentration Studies 
In order to determine whether catechin or epicatechin had any effect on 
adiponectin or resistin release from 3T3-LI adipocytes, cells were treated with 
5 IlM, 50 IlM and 1.5 mM catechin and epicatechin. 
3.4.1.1 Results 
Following this preliminary experiment there was evidence of a dose response 
effect on both adiponectin and resistin release, by both catechin and 
epicatechin. Both 50 IlM catechin and epicatechin appeared to show a trend 
towards increasing adiponectin release, but this was not significant (see Figure 
3.5). The highest concentrations of catechin and epicatechin, l.5 mM, 
significantly decreased resistin release from 3T3-Ll adipocytes (p<O.OOI, n=6) 
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after 24 h treatment (see Figure 3.6). However, this concentration cannot be 
achieved physiologically, so further studies with catechin and epicatechin in 
the physiological range of 1-10 11M were pursued, and a time course set up. 
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Figure 3.5 Effect of 5 pM, 50 pM and 1.5 mM catechin (a) and epicatechin (b) 
on adiponectin release from mature 3T3-Ll adipocytes. 
Results are expressed as adiponectin concentration of medium, removed from 
35 mm dishes after 24 h treatment ± SEM (n=6, duplicate determinants) . 
Standard Curve: R =0.9769. 
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Figure 3.6 Effect of 5 J1M, 50 J1M and 1.5 mM catechin (a) and epicatechin (b) 
on resistin release from mature 3T3-L1 adipocytes. 
Results are expressed as resistin concentration of medium, removed from 35 
mm dishes after 24 h treatment ± SEM (n=6, duplicate determinqnts). 
* p<O. 05 and ***p<O.OOl compared to DMSO. Results analysed using one-
way ANOVA, and Tukey post-hoc test. Standard Curve: R2=0.9764. 
3.4.2 Concentration Range Studies 
Further to the preliminary study, catechin and epicatechin in the 1-1 0 ~ M M
concentration range were investigated, and a treatment time course of 6, 12 and 
24 h was set up. Methods were carried out as detailed in Section 2. 
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Figure 3.7 Effect of 1, 5 and 10 J.1M catechin (a) and epicatechin (b) on 
adiponectin release from mature 3T3-L1 s. 
Results are expressed as adiponectin concentration of medium, removed from 
35 mm dishes after 6, 12 and 24 h ± SEM (n=6, duplicate determinants). 
Standard Curve: R2 =0.9788. ###p<O.OOl, ##p<O.Ol, #p<0.05 compared to 
indicated treatments. ***p<O.OOl and **p<O.Ol compared to DMSO control 
at same time point. Results analysed using one-way ANOVA, and Tukey post-
hoc test. 
There appears to be an increase in basal levels of adiponectin and resist in over 
time, as a result of DMSO treatment, and this remains apparent when catechin 
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or epicatechin treatments are added. Significant changes in adipokine release 
are not seen after 6 or 12 h treatment with either catechin or epicatechin. 10 
JlM epicatechin significantly increased adiponectin release from 3T3-Ll 
adipocytes compared to DMSO control after 12 h (p<O.Ol, n=6) and 24 h 
(p<O.OOI, n=6). There appears to be a dose response effect with epicatechin 
however catechin appears to exert no significant effect on adiponectin release 
from 3T3-Ll adipocytes (see Figure 3.7). 
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Figure 3.8 Effect of 1, 5 and 10 pM catechin (a) and epicatechin (b) on 
resistin release from mature 3T3-L1s. 
Results are expressed as resistin concentration of medium, removed from 35 
mm dishes after 6, 12 and 24 h ± SEM (n=6, duplicate determinants) . 
Standard Curve: R2=0.9881. ###p<O.OOl, ##p<O.Ol, #p<0.05 compared to 
indicated treatments. *p< 0.05 compared to DMSO control at same time point. 
Results analysed using one-way ANOVA, and Tukey post-hoc test. 
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The release of adiponectin as a result of 5 JlM catechin treatment for 24 h 
appears to be comparable with the levels seen in the previous experiment (see 
Figure 3.5 (a), approximately 200 ng adiponectin released and Figure 3.7 (a), 
approximately 25 ng adiponectin released at 24 hours) 
Catechin at 1 and 5 JlM significantly decreased resistin release compared to 
DMSO after 24 h (p<0.05, n-6). 10 JlM catechin significantly increased 
resistin release compared to 1 and 5 JlM catechin after 24 h (p<0.05, n=6). 10 
JlM epicatechin significantly increased resistin release compared to 1 11M 
epicatechin treatment for 24 h (p<0.05, n=6), but this was not significantly 
different to DMSO. 
3.4.3 Effect of EGCG 
At higher (10 JlM) concentrations, epicatechin appears to be a more potent 
regulator of adiponectin release than catechin (compare Figure 3.7 (b) with 
Figure 3.7 (a)), but effects with both flavanols on resistin release, are 
comparable. It has been reported that EGCG is a more potent green tea 
flavanol due to the gallyl and galloyl groups which allow conformational 
flexibility and a large number of hydroxyl groups which may be important for 
hydrogen bonding (Hung et al. 2005). Therefore effects of greater magnitude 
on adipokine release may be expected. 
As there was no significant effect of either catechin or epicatechin on 
adipokine release after 6 or 12 h, a 24 h the dose response for 1, 5 and 10 11M 
was repeated at the 24 h time point, and EGCG was included in this next study. 
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3.4.3.1 Results 
The effect of 10 IlM epicatechin on adiponectin release after the 24 h treatment 
period was not seen to be significantly higher than the DMSO control, as seen 
in the previous study (see Figure 3.7 (b)). 
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Figure 3.9 Effect of 24 h treatment on adiponectin (a) and resistin (b) release 
from mature 3T3-L1 adipocytes using 1, 5 and 10 I'M catechin, epicatechin 
andEGCG 
Results are expressed as adiponectin or resistin concentration of medium, 
removed from 35 mm dishes ± SEM (n=6, duplicate determinants). Standard 
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Curve: R2=O.9928. **p<O.Ol compared to DMSO control at same time point. 
Results analysed using one-way ANOVA, and Tukey post-hoc test. 
1 0 ~ M M catechin did not produce significantly higher levels of resistin release 
than I ~ M M catechin treatment (Figure 3.9 (b)), contrary to previous 
observations (see Figure 3.8 (a)). 
EGCG, at 10 JlM, significantly decreased both adiponectin and resistin release 
compared to the DMSO control (p<O.Ol, n=6) 
Decreased secretion rates were observed in the control state, 123.27±6.65 
ng/ml compared to 308.00±37.61 ng/ml previously observed for adiponectin, 
and 7.26±O.75 ng/ml compared to 32.08±4.71 ng/ml previously determined for 
resistin. Therefore it may have been difficult to see any suppression of 
secretion with the addition of flavanols. EGCG may be a more potent agent; 
consequently it is able to reduce adiponectin and resistin in the under-secreting 
state. 
3.5 Effect of Medium Glucose Concentration 
Methods for 3T3-LI differentiation and maintenance in the literature state that 
cells should be grown, differentiated and maintained in DMEM with a glucose 
concentration of 25 mM, substantially higher than the physiological glucose 
concentration of 5.5 mM. 25 mM glucose provides enough glucose to the cells 
to allow the medium to be replaced every 48 h, however, this makes it difficult 
to draw comparisons between the 3T3-LI adipocyte model and a physiological 
situation. As a 5.5 mM medium glucose concentration would be too low for 
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the cells to survIVe for more than a few hours, it was decided that a 
concentration of 12.5 mM would be tested. This glucose concentration is 
closer to the upper physiological concentration limit (1lmmoVI) and would 
allow the medium to be replaced every 24 h. 
3.5.1 Comparison with Rosiglitazone 
In order to investigate whether medium glucose concentration affects the cells' 
response to rosig1itazone and their ability to secrete adipokines into the 
medium, 3T3-L1 cells were grown and differentiated in Nunclon dishes as 
previously described. Mature 3 T3-L 1 adipocytes were then treated with 1 0 ~ ~
rosiglitazone for 24 h in either 12.5 mM or 25 mM glucose DMEM. Media 
were collected and assayed as previously described. 
3.5.1.1 Results 
Rosiglitazone significantly increased adiponectin release compared to the 
DMSO control (p<O.Ol for 12.5 mM glucose medium and p<0.05 for 25 mM 
glucose medium, n=6). There was no significant difference in adiponectin 
release between cells treated in 12.5 mM and 25 mM glucose media in both the 
untreated and rosiglitazone treated state (see Figure 3.10). 
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Figure 3.10 Adiponectin release from mature 3 T3-L1 adipocytes grown on 
Nunc/on 35 mm dishes, treated with 10 J1M rosiglitazone for 24 h in 12.5 mM 
or 25mM glucose DMEM 
Results are expressed as adiponectin concentration of medium, removed from 
35 mm dishes ±SEM (n=3, duplicate determinants). Standard Curve: 
R2=0.9940. Results analysed using one-way ANOVA, and Tukey post-hoc test. 
*p<0.05 and **p<O. 01 compared to untreated. 
3.5.2 Effect of Catechin and EGCG on Adipokine Release 
According to the previous study there did not appear to be a difference between 
adiponectin release from 3T3-Ll adipocytes treated with rosiglitazone in 12.5 
mM and 25 mM glucose media. It was also important to check whether 
medium glucose levels had an effect on the ability of flavanols to mediate 
adipokine release. 
3T3-Ll cells were grown and differentiated in Nunclon dishes as previously 
described. Mature 3T3-Ll adipocytes were then treated with 10 11M catechin 
or EGCG for 24 h in either 12.5 mM or 25 mM glucose DMEM. Media were 
collected and assayed as previously described. 
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Figure 3.11 Release of adiponectin (a) and resistin (b) from mature 3T3-L1 
adipocytes grown on Nunc/on 35 mm dishes, treated with 10 pM Catechin and 
EGCGfor 24 h in 12.5 mM or 25mMglucose DMEM 
Results as adiponectin or res is tin concentration of medium, removed from 35 
mm dishes±SEM (n=3, duplicate determinants) . Standard Curve: R2=0.9888 
Results analysed using one-way ANOVA, and Tukey post-hoc test. *, ** and 
*** are p<O. 05, p <O. 01 and p<O. 001 respectively, compared to DMSO control 
in same concentration of medium glucose. ## p <0.01 compared to 10 pM 
catechin in same concentration of medium glucose. 
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There is no significant difference between adiponectin or resistin release from 
cells treated with DMSO in 12.5 and 25 mM glucose media. There is also no 
significant difference between release of these adipokines when cells are 
treated with 10 /lM catechin at either medium glucose concentration. With 
EGCG, however, adiponectin release was significantly decreased compared to 
the DMSO control when both groups were treated in 25 mM glucose medium 
(p<0.05, n=6). Adiponectin release in the presence of25 mM glucose medium 
is also significantly different to 10 /lM EGCG treatment in 12.5 mM glucose 
medium (see Figure 3.11 (a)). 
With regard to resistin release, 10 /lM EGCG significantly decreased this in the 
presence of both 12.5 and 25 mM glucose media compared to the DMSO 
control (p<0.01, n=6). There is no significant difference in release of resistin 
from the 3T3-Ll adipocytes between the two medium glucose concentrations 
(see Figure 3.11 (b)). 
3.6 Discussion 
The absence of a clear molecular marker for adipogenesis, along with the 
occurrence of adipose tissue in multiple, dispersed sites around the body has 
made it difficult to isolate and study preadipocytes. Most adipose tissue 
studies are carried out using 3T3-Ll and 3T3-F442A adipocytes. These cells 
are morphologically indistinguishable from fibroblasts but are already 
committed to the adipocyte lineage. When treated with pro-differentiative 
agents they undergo differentiation over a 4-6 day period to form mature fat 
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cells. This is thought to represent a valid model of preadipocyte differentiation 
in vivo, shown via transplantation studies. When 3T3-F442A preadipocytes 
were injected subcutaneously into Balb-C athymic mice, normal fat pads 
developed at the site of injection within 5 weeks (Green and Kehinde 1975). 
Additionally, evidence shows that the fully differentiated adipocytes mimic the 
metabolism of adipocytes isolated from adipose tissue. Preadipocytes in 
culture also develop the proteins necessary for lipolysis of triacylglycerol, 
uptake and intracellular translocation of fatty acids, and regulation of these 
processes by lipogenic and lipolytic hormones. (MacDougald and Lane 1995). 
If mature, differentiated adipocytes are to be studied, it is important that the 
optimum conditions are used for their differentiation. The results shown here 
illustrate the wide variation in differentiation efficiencies as a consequence of 
using different plate types. The variation observed could be explained by the 
different tissue culture coatings applied during manufacture; however, a 
significant difference was seen between the Nunclon ™ ~ ~ 6 well plate cluster 
and Nunclon ™ ~ ~ 35 mm dishes, which have been treated in the same way, 
have the same diameter and therefore the same surface area for cells to attach. 
The variation in differentiation may therefore be dependent on the airflow to 
the cells and media. It is unknown whether this is a pH dependent effect. 
Following this, all experiments were carried out using 3T3-Lls grown and 
differentiated on Nunclon 35mm dishes. 
Adipokines were assayed using the adiponectin and resistin Duosets from R&D 
Systems as these assays were optimised for use with cell culture supernatant. 
The relative concentrations of adiponectin produced were comparable to those 
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in the literature using this same system (Li et al. 2007). Treatment of 3T3-LI 
adipocytes with 10 J-LM rosiglitazone for 24 h, the same as this study, increased 
adiponectin release almost 2 fo ld, a similar increase to that seen in Figure 3.10. 
The actual amounts detected are 10 fold lower in the referenced paper; 7 and 
13 ng/ml, for control and rosiglitazone, respectively, compared to 75 and 120 
ng/ml in Figure 3.10. No indication of tissue culture dish size or medium 
vo lume is given in the referenced paper. 
There did, however, appear to be a progressive decrease in secretion of both 
adipokines from the 3T3-L1 adipocytes. The reasons for the decreased 
secretion rates are unknown; the 3T3-L1 adipocytes were not used beyond 8 
passages to prevent them from losing their function. It is possible that the 
assay had reduced sensitivity, however, all assay reagents were stored 
according to the manufacturer's instructions for a maximum of 6 months. 
The higher concentrations of catechin and epicatechin used in the preliminary 
study appeared to increase adiponectin release, and significantly decreased 
resistin release. These concentrations were not pursued though, as they were 
too high to represent any levels obtainable physiologically. As further studies 
were carried out with EGCG, construction of a dose-response curve may have 
provided a firmer base on which to design further experiments. It has been 
calculated that a cup of green tea, comprising 2.5 g of green tea leaves/200 ml 
of water, may contain 90 mg of EGCG (Wu and Wei 2002). A 
pharmacokinetic study in humans showed that a bulk dose of 100 mg EGCG 
resulted in a maximum plasma concentration of 189.52 ng/ml (0.4 J-LM) and a 
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bulk dose of 1600 mg EGCG was required to produce a maximum plasma 
concentration of2911.35 ng/ml (6.35 JlM) free EGCG (Ullmann et al. 2003). 
Effects on adipokine release in 3 T3-LIs, reported in the literature, appear to be 
flavonoid specific. Catechin, when incubated with 3T3-L1 adipocytes at 50 
JlM for 24 h increased adiponectin release to over 200% of the control, 
however the same dose and duration of epicatechin 3-gallate, quercetin and 
kaempferol suppressed adiponectin release to 790/0, 54% and 42% of the 
control, respectively. EGCG and epicatechin, however, had no effect on 
adiponectin release (Cho et al. 2007). Feeding studies, on the other hand, 
provide evidence that EGCG can increase circulating levels of adiponectin 
(Potenza et al. 2007; Shimada et al. 2007). 
There is evidence that EGCG suppresses resistin mRNA and protein expression 
in a dose and time dependent manner in 3T3-L1 adipocytes (Liu et al. 2006). 
20 JlM EGCG treatment led to a 35% suppression of resistin mRNA and 100 
JlM led to 50% suppression of resistin mRNA 3 h after treatment. Intracellular 
resistin protein decreased with 100 JlM treatment for 3 h to 750/0 of the control, 
however there was no significant effect on resistin protein release. 
Interestingly, suppression of resistin mRNA was similar with EGCG, 
epicatechin gallate and epicatechin, but little suppression was seen with 
epigallocatechin. The referenced results use flavanols at much higher 
concentrations than this study, concentrations which are too high to be 
achieved by consumption of green tea. 
The studies in this chapter, investigating the effects of the flavanols catechin, 
epicatechin and EGCG, have been carried out in medium containing 25 mM 
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glucose. The generally accepted protocol for 3T3-L1 growth, maintenance and 
differentiation suggests that this medium glucose concentration be maintained 
throughout the culture of these cells, and indeed, the majority of studies which 
use the 3T3-L1 adipocyte system use this medium glucose concentration 
throughout their various treatments. Physiological glucose concentration is 5.5 
mM, so in order that the studies in this chapter are as relevant and transferable 
to a physiological situation, they should be carried out as close to physiological 
conditions as possible. Maintenance of cells under this lower, physiological 
glucose level requires that the medium be replaced at least every 12 h, such 
that the cells have enough glucose. This is difficult to do and also results in 
complications when carrying out 24 h treatments which require media 
collection and analysis. For this reason, a "compromise" concentration of 12.5 
mM glucose containing media was decided upon, so that the cells were able to 
remain 24 h in the same media without feeding. This meant that the average 
glucose concentration was about 9 ruM over the incubation period. 
Investigating the effects of catechin and EGCG in the two different glucose 
concentrations showed that in the case of resist in, there was no difference in 
the release, it was suppressed under both conditions. Adiponectin, however, 
appears to be more sensitive to glucose conditions, as treatment with EGCG in 
the lower glucose concentration had no effect on adiponectin release. 
Treatment with EGCG in the higher, 25 mM glucose containing media resulted 
in significantly suppressed adiponectin release as compared to the control and 
EGCG treatment in the lower glucose containing media. Interestingly, 
treatment with catechin, under both media glucose concentrations, had no 
effect on either adiponectin or resistin release from the 3T3-L1 adipocytes. 
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The results for catechin are somewhat contradictory, however, as a study 
earlier in the chapter showed that 10 ~ M M catechin, in the 25 mM glucose 
medium, significantly increased resistin release. As medium glucose 
concentration affects the mRNA and secretion levels of adiponectin (Park et al. 
2004; Huypens et al. 2005) and resistin (Shojima et al. 2002), a possible 
explanation for this inconsistency may be due to the fact that the 3T3-Ll 
adipocytes were being maintained in supraphysiologicallevels of glucose. 
Adiponectin plays a significant Tole in linking obesity and insulin resistance, 
obesity related increments in adipocyte cell size are accompanied by reduced 
secretion and low circulating levels, which then promotes increased cellular 
lipid content and insulin resistance (Yamauchi et al. 2001), additionally, serum 
adiponectin levels increase with weight loss (Arita et al. 1999). Adiponectin 
gene expression is regulated by several extracellular signalling factors, 
including insulin, TNFa and ~ - a d r e n e r g i c c agonists (Havel 2004). PP ARy has 
been shown to induce adiponectin promoter activity though an unidentified 
element responsive to PPARy (Maeda et al. 2001). TZD agonists ofPPARy 
increase adiponectin expression and circulating levels in rodents and plasma 
adiponectin levels in non-diabetic subjects and in patients with Type 2 
diabetes. C/EBPa has been reported to regulate adiponectin gene transcription 
through an intronic enhancer (Qiao et al. 2005). SREBP-1 c binds to the 
adiponectin promoter and mediates the insulin dependent adiponectin 
expression (Seo et al. 2004). Kruppellike factor (KLF)-7 has been reported to 
inhibit adiponectin gene expression in adipocytes (Kawamura et al. 2006). 
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Resistin, in mice, is expressed almost exclusively in white adipose tissue and 
released into the blood. In rodent models of obesity and diabetes, serum 
resistin levels are elevated, and administration of resistin to wild type mice 
worsened glucose homeostasis and insulin sensitivity and in 3 T3-L 1 adipocytes 
suppressed insulin stimulated glucose uptake. This effect was prevented by an 
anti-resistin antibody (Steppan et al. 2001). This suggests that resistin impairs 
insulin sensitivity and may contribute to the development of insulin resistance 
or diabetes in obese rodents. In both humans and mice, serum resistin protein 
levels are positively associated with adiposity, however, resistin mRNA in 
humans does not correlate with BMI (Savage et al. 2001). In humans, resistin 
expression in adipocytes is almost undetectable, and is expressed at the highest 
level in bone marrow (Patel et al. 2003). This may help to explain why murine 
studies suggest that resistin regulates insulin action but the conclusions from 
human studies are unclear, making it difficult to translate murine studies to 
humans. TZDs, by activating PP ARy, cause decreased resistin expression and 
decreased insulin resistance (Wolf 2004). Treatment of mice with TZDs 
lowered resistin protein levels, similar to the effects observed in vitro, using 
3T3-L1 cells (Steppan et al. 2001). 
The mechanisms of adiponectin and resist in regulation have not been fully 
elucidated as yet, however they are both altered by TZD treatment and 
therefore are under the control of PP ARy phosphorylation. PP ARy is a 
substrate of ERK1I2 and phosphorylation is believed to decrease its 
transcriptional activity and inhibits adipocyte differentiation (Camp and Tafuri 
1997), this can also result in increased adiponectin release and suppression of 
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resistin release in adipocytes, shown recently by Sharma and Staels (Sharma 
and Staels 2007). 
The studies in this chapter show, that while adiponectin release can be altered 
by EGCG, this only occurs at glucose levels which are much higher than 
physiological levels and therefore cannot be translated to a physiological 
environment. Resistin release can be altered at both supraphysiological and 
closer to physiological levels in 3T3-LI adipocytes. It is possible that EGCG 
could affect the expression and/or secretion of resistin in other tissues in 
humans, however, as 3T3-Lls are murine derived cells, again, it is difficult to 
draw comparisons to human physiology. 
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Signalling: 
investigation into the ERK pathway 
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4 Signalling 
4.1 Introduction 
Changes in adipokine levels are either due to changes in levels of secretion or 
synthesis. In order to determine the mechanism by which adipokine levels 
were being altered, the ERK1I2 MAPK pathway, summarised in Figure 1.2, 
was investigated. There are many known targets of the ERK1I2 pathway, 
transcription factors such as AP-1, NF-KB, C I E B P ~ ~ and PPARy. There is 
evidence that PP ARy can regulate both the gene expression and protein levels 
of adiponectin (Maeda et al. 2001; Havel 2004) and resistin (Steppan et al. 
2001; Wolf 2004). Additionally, C/EBPa has been reported to regulate 
adiponectin gene transcription through an intronic enhancer (Qiao et al. 2005). 
C/EBPa is indirectly regulated by ERK1/2 via C / E B P ~ ~ (Park et at. 2004). 
PP ARy and CIEBPa both play important roles in adipogenesis. There is a 
cooperative action between these two transcription factors, where a positive 
feedback loop induces the expression of each factor. This drives the 
expression of genes that are necessary for the generation and maintenance of 
the adipocyte phenotype. 
There is evidence to suggest that flavanols are able to alter the phosphorylation 
status of ERK1I2. Studies in preadipocytes (Hung et at. 2005), HUVECs 
(Chae et al. 2007) and human keratinocytes (Huang et at. 2007) demonstrate 
the effect ofEGCG in decreasing ERK1I2 phosphorylation. Studies in primary 
cortical neurons (Spencer et al. 2003; Schroeter et al. 2007; Vauzour et at. 
2007) provide evidence that flavonoids are able to alter the phosphorylation 
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status of ERK1I2, and this is not necessarily in the same direction. It is 
therefore difficult to predict the effect that green tea catechins might have on 
the ERK1/2 phosphorylation status in 3T3-Ll adipocytes, because although 
they act to decrease phosphorylation in preadipocytes, the same may not occur 
in adipocytes as these two cell types are very different. 
Following investigation of the ERK1I2 signalling cascade, potential 
mechanisms of upstream activation were explored. 
4.2 Phosphorylation of ERKl/2 using controls 
Prior to investigating the effects of epicatechin and EGCG on ERK1I2 
phosphorylation, it was important to ensure that the phosphorylation status of 
the 3T3-Ll system could be altered. U0126 is a chemically synthesised 
organic compound that inhibits the kinase activity of MEK1I2 and therefore 
inhibits phosphorylation of ERK1I2. EGF is known to be a potent stimulator 
ofERK1I2 phosphorylation in 3T3-Ll adipocytes (Wiese et al. 1995), and was 
therefore used as a positive control. 
Cells were differentiated as detailed in Section 2, treated with 10 mM UO 126 
for 15 min, with and without 10 nM EGF for 10 min, with six 35 mm Nunclon 
dishes per treatment. Samples were prepared in lysis buffer (Section 2.3.3) and 
protein was determined by the Lowry method (Section 2.3.5.1). Proteins were 
separated by Western blotting (Section 2.3.6-7) and incubated with anti 
cyclophilin B, ERK1I2 and pERKl12 antibodies as detailed in Section 2, Table 
2.1. Protein bands were visualised using ECL. 
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To account for variations between gels, an internal control, constituting small 
volumes of each sample pooled together, was loaded onto each geL and the 
cyclophilin B bands normalised to this, before being used to normalise all other 
protein bands. All densities were then expressed as a percentage of the mean 
vehicle control density for that sample group. 
U0126 significantly diminished (p<O.Ol, n-6) and EGF significantly 
stimulated (p<O.OOl, n-6) ERK1/2 phosphorylation as expected. UOl26 was 
also able to significantly reduce the EGF stimulated ERK1I2 phosphorylation 
(p<O.OOl, n=6) (see Figure 4.1 (b) and (d)). Levels of ERK1I2 remained 
relatively unchanged with treatment (see Figure 4.1 (a) and (c) and Figure 4.2). 
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Figure 4.1 Effect on ERK1/2 andpERK1/2following 10mM U0126 (15 min) 
treatment with and without 10nM EGF (10 min) of mature 3T3-L1 cells in 12.5 
mM glucose DMEM 
Cell lysate was subjected to SDS-PAGE and Western blotting with anti-ERK1/2 
(a), p-ERK1/2 (b) and cyclophilin B antibodies. Densitometry of ERK1/2 (c) 
and pERK1/2 (d) blots, normalised to internal controls and cyclophilin B 
levels, expressed relative to DMSO 
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Figure 4.2 Change in pERK1/2 levels relative to ERK1/2 following treatment 
with 10 mM U0126 (15 min) with and without 10 nM EGF (10 min) of mature 
3T3-L1 adipocytes in 12.5 mM glucose DMEM 
Results analysed using one-way ANOVA, and Tukey post-hoc test. ** p <O.Ol 
compared to control, *** p<O.OOl compared to control, ### p<O.OOl 
compared to EGF alone. 
4.3 ERKl/2 phosphorylation following 1 h flavanol treatment. 
It was shown in studies on adipokine release (Chapter 3), that EGCG had the 
most potent effect on both resistin and adiponectin release. It was thus decided 
that 3T3-Ll adipocytes should be treated with 10 11M EGCG and subsequent 
phosphorylation ofERK1I2 should be measured. Epicatechin also appeared to 
have a more potent effect on both resistin and adiponectin release, compared to 
catechin, so epicatechin treatment was also used to investigate ERKl /2 
phosphorylation. 
Cells were differentiated as detailed in Section 2, treated with 10 11M 
epicatechin or EGCG for one hour and further processed as described earlier. 
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Figure 4.3 Effect on ERK112 and pERK112 following 1 hr treatment of mature 
3T3-L1s with 10 f.1.M epicatechin and EGCG in 12.5 mM glucose DMEM 
Cell lysates were subjected to SDS-PAGE and Western blotting with anti-
ERK112 (a) , pERK112 (b) and cyclophilin B antibodies. Densitometry of 
ERK112 (c) and pERK112 (d) blots, normalised to internal controls and 
cyclophilin B levels, expressed relative to DMSO control. 
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Figure 4.4 Change in pERK112 levels relative to ERK112 following 10 f.1M 
epicatechin and EGCG treatment of mature 3T3-L1 cells in 12.5 mM glucose 
DMEM 
There were no detectable changes in ERK1I2 phosphorylation after 1 hr 
treatment with 10 /-lM epicatechin or EGCG (see Figure 4.3 and Figure 4.4). It 
is possible that this may be too long and the phosphorylation event had passed, 
so the treatment time was decreased to 30 min and a dose response with 
epicatechin and EGCG was set up. There appeared to be a high degree of 
variability between the lanes of Figure 4.3 (b). As protein concentrations of 
samples were equalized before loading, this may be due to inconsistent transfer 
of the samples from the gel to the nitrocellulose membrane. 
4.4 ERKl/2 phosphorylation following 30 min flavanol 
treatment 
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As one hour may have been too long a treatment period, and the 
phosphorylation event may have passed, this was reduced to 30 min in a further 
attempt to detect phosphorylation. Research by Prusty et al (2002) shows that 
phosphorylation of ERK1I2 can be detected as early as 5 min (Prusty et al. 
2002). Additionally a dose response of epicatechin and EGCG was set up with 
0.1, 1, 10 and 50 /lM epicatechin or EGCG. Samp les were prepared and 
processed as previously stated. 
Epicatechin at 0.1 and 1 /lM had no effect on ERK1I2 phosphorylation after 30 
min treatment (results not shown). 10 /lM epicatechin significantly increased 
ERK1I2 phosphorylation after 30 min exposure (p<O.OOl, n=6), (4-fold higher 
than the vehicle control). 50 /lM epicatechin showed increased 
phosphorylation but this was not significant (see Figure 4.5 (b) and (d)). 
Levels of ERK1I2 remained relatively stable during treatment (see Figure 4.5 
(a) and (c) and Figure 4.7). 
EGCG at 0.1 /lM, when incubated with 3T3-L1 cells for 30 min significantly 
increased ERK1I2 phosphorylation (p<O.Ol, n=6) (see Figure 4.6 (b) and (d)), 
2.8-fold higher than the vehicle control. 10 and 50 /lM EGCG had no effect on 
ERK1I2 phosphorylation after 30 min (results not shown). Levels of ERK1I2 
remained constant throughout the treatment (see Figure 4.6 (a) and (c) and 
Figure 4.8) 
Following this study, the Odyssey system became available and subsequent 
Western blots were carried out using this as it is a more sensitive system. 
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Figure 4.5 Effect on ERK1/2 and pERK1/2 following 30 minute treatment of 
mature 3T3-L1 cells with 10 and 50 pM epicatechin in 12.5 mM glucose 
DMEM 
eelllysate was subjected to SDS-PAGE and Western blotting with anti-ERK1/2 
(a) , p-ERK1/2 (b) and cyclophilin B antibodies. Densitometry of ERK1/2 (c) 
and pERK1/2 (d) blots, normalised to internal controls and cyclophilin B 
levels, expressed relative to DMSO control. Results analysed using one-way 
ANOVA, and Tukey post-hoc test. **p<O.OOl compared to DMSO control. 
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Figure 4.6 Effect on ERKI/2 and pERKI/2 following 30 minute treatment of 
mature 3T3-Lls with 0.1 and 1 11M EGCG in 12.5 mM glucose DAfEM 
Cell lysate was subjected to SDS-PAGE and Western blotting with anti-ERKI/2 
(a), p-ERKI/2 (b) and cyclophilin B antibodies. Densitometry of ERKI/2 (c) 
and pERKI/2 (d) blots, normalised to internal controls and cyclophilin B 
levels, expressed relative to DMSO control. Results analysed using one-way 
ANOVA, and Tukey post-hoc test. **p<O.OOI compared to DMSO control. 
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Figure 4.7 Change in pERK112 levels relative to ERK112 following treatment 
of mature 3T3-L1 adipocytes with 10 and 50 pM epicatechinfor 30 min in 12.5 
mM glucose DMEM 
Results analysed using one-way ANOVA, and Tukey post-hoc test. **p<O.OOl 
compared to DMSO control. 
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Figure 4.8 Change in pERK112 levels relative to ERK112 following treatment 
of mature 3T3-L1 adipocytesfor 30 min with 0.1 and 1 pM epicatechin in 12.5 
mM glucose DMEM 
Results analysed using one-way ANOVA, and Tukey post-hoc test. ***p<O.OI 
compared to DMSO control 
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4.5 Confirmation of ERKl/2 phosphorylation, use of Odyssey 
system 
Prior to investigating the downstream effects of ERK1I2 activation a further , 
confIrmation treatment was carried out, using the concentrations of epicatechin 
and EGCG that produced the maximal ERK1I2 phosphorylation response. 
Additionally it was important to ensure that the same results were produced 
with the Odyssey system as with ECL reagents. 
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Figure 4.9 Effect on ERK112 and pERK112 following 30 minute treatment of 
mature 3T3-L1 cells with 10 f-LM epicatechin or 0.1 f-LM EGCG in 12.5 mM 
glucose DMEM 
(a) Cell lysate was subjected to SDS-PAGE and Western blotting with anti-
ERK112, anti p-ERK112 and cyclophilin B antibodies; and Odyssey secondary 
antibodies. (b) Graphical representation ofpERK112 levels relative to ERKll2 
levels, normalised to cyclophilin B levels, measured by densitometry. Results 
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Cells were differentiated as in Section 2, treated with 10 11M epicatechin or 0.1 
11M EGCG for 30 min and samples were prepared and processed as described 
earlier, with the exception of the use of Odyssey secondary antibodies as 
detailed in Section 2, Table 2.2. Protein bands were visualised and their 
density determined with the Odyssey scanner and software. 
0.1 11M EGCG significantly increased ERK1I2 phosphorylation after 30 min 
(see Figure 4.9) (p<0.01, n=3), confirming the results seen in Figure 4.5 to 
Figure 4.8. This increase, however, was not of the same magnitude, only 1.8-
fold as compared to 2.5-fold as seen previously. 30 min treatment with 10 11M 
epicatechin increased ERK1I2 phosphorylation 1.3-fold, but this was not 
significant and not supportive of the previous experiment. 
4.6 GTPyS Binding Assay 
Having observed that epicatechin and EGCG were able to stimulate 
phosphorylation of ERK1I2, the next step was to try and understand the 
mechanism of this stimulation by investigating processes upstream of the 
ERK1/2 signalling pathway. There are 3 main pathways which converge at the 
MEK pathway. These are the cAMP pathway, PLC pathway and Ras, all 0 f 
which are downstream of GPCR activation. The GTPyS binding assay 
measures the level of G protein activation following agonist occupation of a G 
protein-coupled receptor. 
103 
Signalling 
Cell membranes from human embryonic kidney (HEK) cells expressing rat 
recombinant CB2 receptors were incubated with [35 S] GTPyS and 1 0 ~ M M
catechin, epicatechin or EGCG and 1 ~ M M HU210 (CB1 agonist) and processed 
as detailed in Section 2.4. 
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Figure 4.10 GTPyS binding in 10 pg HEK membrane preparations in the 
presence of 1 0 pM catechin, epicatechin and EGCG for 90 min. 
Results are shown as counts per minute per preparation ±SEM (n=4) . Results 
analysed using one-way ANOVA, and Tukey post-hoc test. *** p <0.001 
compared to basal and all other treatments 
1 0 ~ M M catechin and epicatechin had no effect on GTPyS binding, and 1 0 ~ M M
EGCG appeared to negatively regulate this process in HEK cells, by 
significantly decreasing GTPyS binding compared to basal, catechin and 
epicatechin treatment (p<O.OOl , n=4) (see Figure 4.10). 
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4.7 Discussion 
The aim of this chapter was to investigate the potential mechanisms by which 
the flavanols EGCG and epicatechin alter secretion of the adipokines, 
adiponectin and resistin, in 3T3-Ll adipocytes. 
This chapter fIrstly demonstrates that the 3T3-Ll adipocyte model performs as 
expected with regards to alteration of the ERK1I2 phosphorylation status by 
the known inhibitor U0126 and known stimulator, EGF. Secondly, EGCG and 
epicatechin were both able to alter ERK1I2 phosphorylation by increasing it to 
levels above those seen with the vehicle control. Both 0.1 11M EGCG and 10 
11M epicatechin increased ERK1I2 phosphorylation by 2.S-fold compared to 
the vehicle control, levels comparable to those produced by 10 nM EGF 
treatment (2.8-fold higher than the vehicle control). A benefIcial progression 
from this study would be to try and establish whether EGCG and epicatechin 
are acting through the same mechanism as EGF by investigating whether there 
is any additive effect of EGCG or epicatechin with EGF, or indeed, whether 
this is the maximum achievable ERK1I2 phosphorylation by treating with the 
optimum concentrations of both EGCG and epicatechin. 
EGF, acting via the EGF receptor (a receptor tyrosine kinase) directly increases 
ERKl/2 phosphorylation by activating Ras in the ERK1/2 cascade. The 
mechanisms of flavanol action are currently unknown, the 67 kDa laminin 
receptor may be playing a role in this as it has been suggested as an "EGCG 
receptor" and has been discovered in cancer cells (Tachibana et al. 2004) nerve 
cells, hepatocytes and muscle cells (Mecham 1991). There is also some 
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evidence demonstrating that the 67 kDa laminin receptor signalling pathway 
involves the ERK1I2 pathway. Laminins have been identified in adipocytes 
(Niimi et al. 1997; Burton et al. 2004), but as yet, there is no evidence of this 
67 kDa laminin receptor in adipocytes. A specific plasma membrane binding 
site for polyphenols has been recently described in rat brain (Han et al. 2006), 
suggesting that they may act through a steroid like receptor in neurons. 
EGCG at 50 /lM has been shown to decrease ERK1I2 phosphorylation in 3T3-
L1 preadipocytes (Hung et al. 2005). This chapter demonstrates that EGCG is 
able to increase ERK1I2 phosphorylation in 3T3-L1 adipocytes. This may help 
to explain the variability and inconsistency seen in the results of the previous 
chapter. Although the 3T3-L1 adipocytes used throughout these studies were 
considered to be at least 90% differentiated in each case, this was only checked 
by looking at their morphology and it is therefore possible that between 
studies, dishes with differences in the percentage of differentiated adipocytes 
may have been used. Therefore, any conflicting data may be a result of having 
a mixed culture of adipocytes in various stages of differentiation. This could 
be confirmed by comparing ERK1I2 phosphorylation of 3 T3-L 1 preadipocytes 
and adipocytes. 
The effects of epicatechin on ERK1I2 phosphorylation have been investigated 
in cortical neurons (Schroeter et al. 2007). A 15 min treatment of 100-300 nM 
epicatechin stimulated a robust phosphorylation of ERK1I2. At higher 
epicatechin concentrations, the extent of phosphorylation was much lower, 
returning to basal at levels greater than 1 /lM. This ERK1I2 phosphorylation, 
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in combination with the PI3 kinase pathway, was shown to regulate CREB 
phosphorylation. 
The concentrations of flavonoids used for in vitro studies are very important as 
some exert anti apoptotic actions at low concentration but act as pro apoptotic 
stimuli at higher concentrations. Quercetin and its metabolites 3' -O-methyl 
quercetin and 4'-O-methyl quercetin have been previously shown to inhibit 
ERK1/2 phosphorylation, an action underlying their potentially pro-apoptotic 
actions in neurons. Interestingly, lower concentrations of quercetin stimulated 
CREB (Spencer et al. 2003), which could reflect an anti apoptotic protective 
response, as CREB-dependent upregulation of gene expreSSIon IS 
neuroprotective. 
EGCG and epicatechin have different optimum concentrations; there was a 100 
fo ld difference in optimum concentrations to produce the same, significant 
increase. It seems that in most cases, gallated catechins, especially EGCG, are 
more active than other catechins (Hung et al. 2005). EGCG contains the 
largest number of hydroxyl groups on its three aromatic rings among the tea 
catechins, and these hydroxyl groups may be important for hydrogen bonding. 
Also, EGCG has both gallyl and galloyl groups, which have some 
conformational flexibility that may also be important for interaction with other 
molecules. 
Having established that EGCG and epicatechin were able to stimulate ERK1/2 
phosphorylation, it was important to try and establish the mechanism of 
upstream activation of this pathway. There are several upstream components 
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that join the ERK1I2 pathway; GPCRs, receptor tyrosine kinases (both ligand 
dependent and independent (Gardner et al. 2003)) and integrins. 
The first method used to potentially elucidate which upstream component was 
being activated was to determine whether the flavano Is under investigation 
bound to a GPCR. A GTPyS binding assay was therefore established, using 
HEK cells, expressing rat recombinant CB2 receptors. EGCG, at 10 IlM, 
negatively regulated GTPyS binding in HEK cells, whereas epicatechin and 
catechin at the same concentrations did not alter binding signillcantly 
compared to basal levels. This negative regulation suggests that EGCG could 
act as an antagonist at a GPCR, in this case the CB2 receptor, and this pathway 
may be worth pursuing. Ideally, this assay would have been transferred to the 
3T3-Ll system, however, due to time restraints, this was not possible. In 
addition, a dose-response curve of each flavanol should have been constructed. 
As EGCG treatment produced greater stimulation of pERK at 0.1 IlM , 
compared to 1 IlM, investigation of GTPyS binding with 0.1 IlM EGCG may 
have produced more information regarding the mechanism of action of EGCG 
in this pathway. 
Measurement of cyclic AMP (cAMP) generation from ATP by adenylyl 
cyclase following GPCR activation was another method employed to help 
elucidate the mechanism of ERK1I2 activation by the flavanols. Cyclic AMP 
is a small molecule that has a key role in the regulation of intracellular signal 
transduction. cAMP is derived from ATP by the catalytic action of the 
signalling enzyme adenylyl cyclase. This cyclisation reaction involves the 
intramolecular attack of the 3' -OH group of the ribose unit on the a-phosphoryl 
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group of ATP to form a phosphodiester bond, this is driven by the subsequent 
hydrolysis of the released pyrophosphate. The activity is terminated by the 
hydrolysis of cAMP to 5' -AMP by specific cAMP phosphodiesterases. 
Receptors may be linked to the generation of cAMP by one of two routes. One 
group of receptors is associated with increased adenylyl cyclase activity and 
elevated cAMP levels mediated through a guanine nucleotide binding protein, 
Gs. Activation of the second group leads to inhibition of adenylyl cyclase and 
a reduction in cAMP generation. The mechanism of inhibition of adenylyl 
cyclase activity appears to be mediated through a distinct guanine nucleotide 
binding protein, Gi. These two G-proteins act on adenylyl cyclase either to 
stimulate or inhibit the conversion of ATP to cAMP. 
This assay was a three step process; firstly, radioceptor binding protein was 
prepared from the supernatant of porcine adrenal homogenate; secondly, cAMP 
was generated in the cells by incubating the cells with radiolabelled cAMP in 
the presence of the flavanols or IBMX (a non-selective phosphodiesterase 
inhibitor), followed by the addition of forskolin (a non-selective adenyl cyclase 
activator) and ice co ld concentrated hydrochloric acid to stop the reaction. 
Thirdly, cAMP estimation was carried out by incubating binding protein with 
each sample, filtering samples through Whatman filters and determining bound 
radioactivity through liquid scintillation spectrophotometry. 
A considerable period of time was spent attempting to optimise this assay, but 
a functional readout of bound radioactivity in this assay could not be obtained, 
and therefore results could not be included. 
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As previously discussed, EGF stimulation of the ERK1I2 pathway requires the 
EGF receptor which is a tyrosine kinase. EGCG could, potentially, be an 
agonist for a tyrosine kinase receptor. There is evidence in cervical cells that 
EGCG inhibits EGF signalling by inhibiting EGF -dependent activation of the 
EGF receptor, which then suppresses the EGF receptor dependent activation of 
ERK1I2. Interestingly, downstream of ERK1I2, there was only selective 
inhibition of its phosphorylation of specific substrates, suggesting that EGCG 
acts simultaneously at multiple levels to inhibit EGF dependent signalling (Sah 
et al. 2004). In addition to inhibiting EGFR, cell-free studies demonstrated 
that EGCG directly inhibited ERK1I2 , suggesting that EGCG acts 
simultaneously at multiple levels to inhibit EGF-dependent signalling. 
As previously mentioned, the ERK1I2 pathway can be also stimulated in a 
ligand-independent manner via the EGF receptor by PP ARa and y ligands 
(Gardner et al. 2003), so it could be possible that the flavanols are acting in a 
similar manner. 
ERK1I2 is not the only signalling pathway that has been implicated in EGCG 
and epicatechin action. The Akt (Sah et al. 2004; Morikawa et al. 2007; Pan et 
al. 2007) and PI3-kinase (Kim et al. 2007; Schroeter et al. 2007) pathways also 
play an important role and these are worth pursuing in future studies. 
Following attempts to identify the mechanism of upstream ERK1/2 activation, 
attention was focussed on the potential downstream effects of ERK1/2 
activation. The ERK1I2 pathway has many substrates, including NF-KB, AP-l, 
STAT and CREB, and activation of this pathway could have a number of 
potentially beneficial outputs. In order to obtain a physiologically relevant 
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functional readout, the link between the ERK1I2 pathway and glucose uptake 
was investigated and is the focus of the following chapter. Work in 3T3-Ll 
adipocytes showed that chronic activation of ERKl/2 leads to upregulation of 
GLUTl expression and down regulation of GLUT4 expression, resulting in 
slightly increased basal glucose transport but decreased insulin stimulated 
transport (Fujishiro et al. 2003). However, treatment of mature 3T3-Ll 
adipocytes with the MEK inhibitors PD98059 and U0126 inhibited insulin 
mediated glucose uptake (Harmon et al. 2004). Investigating the effects of 
EGCG and epicatechin on glucose uptake in 3T3-Ll adipocytes may help to 
clarify this. 
III 
Glucose Uptake 
Glucose Uptake: 
effect of epicatechin and EGCG 
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5 Glucose Uptake 
5.1 Introduction 
In order to understand the effects ofEGCG and epicatechin on mature 3T3-LI 
adipocytes and fmd a potential physiological outcome of this effect, glucose 
uptake was investigated. It was shown in the previous chapter that epicatechin 
at 10 JlM and EGCG at 0.1 JlM, when incubated with 3 T3 -L 1 adipocytes 
resulted in an increase in ERK1I2 phosphorylation. Therefore, epicatechin at 
concentrations of I, 10 and 50 JlM and EGCG at concentrations 0 f 0.1, 1 and 
10 JlM were used to treat 3T3-LI adipocytes and their effect on 2-
deoxyglucose (2DG) uptake was measured as an index of glucose uptake. 
Increased ERK1I2 phosphorylation was seen after 30 min treatment; therefore 
2-deoxyglucose uptake was measured after this time to see if any effect was a 
direct result of ERK1I2 phosphorylation. Additionally, 3T3-LI adipocytes 
were incubated with epicatechin and EGCG for 6 and 24 h to allow for the 
phosphorylation signal to be propagated. 
5.2 Preliminary assays 
Prior to investigating the effects of EGCG and epicatechin on 2-deoxyglucose 
uptake, it was important to establish whether the glucose uptake system could 
be altered in the 3T3-Ll adipocytes. For this reason, fIrstly an insulin dose 
response was carried out, and the effect of a known inhibitor of glucose 
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transport, cytochalasin B (Ebstensen and Plagemann 1972; Kletzien et al. 
1972; Mizel and Wilson 1972; Lachaal et al. 1996), was investigated. 
5.2.1 Insulin dose response 
Mature 3T3-L1 adipocytes, differentiated as detailed in Section 2.3.1, were 
treated with 0.01 % DMSO, 10, 50, 100 and 200 nM insulin for 10 min, 
followed by 27.8 kBq [3H] 2-DG and 1.5 mM 2-DG for 10 min. Assay 
information is detailed in section 2.3.5. 
All insulin concentrations used significantly increased glucose uptake 
compared to DMSO control (Figure 5.1a) (p<O.OOI). Although a dose 
response trend was apparent with 10 nM insulin resulting in the lowest level 0 f 
glucose uptake and 100 nM the highest there was no significant difference 
between the concentrations. It was therefore decided that 10 nM insulin would 
be used in subsequent experiments with EGCG and epicatechin. 
5.2.2 Effect of Cytochalasin B 
Mature 3T3-L1 adipocytes, differentiated as detailed in section 2.3.1 were pre-
treated with 20 ~ M M cytochalasin B for 10 min, followed by 10 min with and 
without 100 nM insulin, for 10 min. 27.8 kBq [3H] 2-DOG and 1.5 mM 2-
DOG was added for 10 min, and uptake of2-deoxyglucose was measured. 
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Cytochalasin B significantly decreased basal and insulin mediated glucose 
uptake (p<O. 001, Figure 5 .1 b). As the glucose uptake system was responding 
as expected, the effect of epicatechin and EGCG was investigated. 
(a) Treatment 
r** 
(b) Treatment 
Figure 5.1 2-Deoxyglucose uptake by mature 3T3-L1 adipocytes in 12 well 
plates, in response to varying insulin concentrations (a) and using cytochalasin 
B as an inhibitor (b). 
Adipocytes were treated with 10, 50, 100 and 200 nM insulin for 10 min (a) or 
10 min treatment with 20 pM cytochalasin B, with and without 100 nM insulin 
for 10 min (b). Uptake is measured as disintegrations per minute (DPM) per 
well. Data were analysed using a one-way ANOVA, *** p <O.OOl (n =6). 
115 
Glucose Uptake 
5.3 Effect of Epicatechin and EGCG 
Mature 3T3-L1 adipocytes, differentiated as outlined in Section 2.3.1 were 
treated with 1, 10 and 50 IlM epicatechin and 0.1, 1 and 10 IlM EGCG for 30 
min, 6 hand 24 h. 10 nM insulin was added, or not, for 10 min, followed by 
27.8kBq eH] 2-DG and 1.5 mM 2-DG for 10 min, and uptake of 2-
deoxyg1ucose was measured. 
Neither epicatechin nor EGCG had any effect on either basal or insulin 
mediated glucose uptake at any concentration or time point investigated 
(Figure 5.2 and Figure 5.3) 
116 
Glucose Uptake 
(a) 
(b) 
(c) 
24 h Treatment 
Figure 5.2 2-Deoxyglucose uptake by mature 3T3-L1 adipocytes zn 12 well 
plates, following 30 min (aj, 6h (bj and 24h (cj treatment with either 1, 10 or 
50 pM epicatechin with and without 10 nM insulin for 10 min. 
Uptake is measured as disintegrations per minute (DP M) per well. Data were 
analysed using a one-way ANOVA, *** p<O.OOl (n=6j. 
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(a) 
(b) 
(c) 
Figure 5.3 2-Deoxyglucose uptake by mature 3T3-L1 adipocytes In 12 well 
plates, following 30 min (a), 6 h (b) and 24 h (c) treatment with either 0.1, 1 or 
10 pM EGCG with and without 10 nM insulin for 10 min. 
Uptake is measured as disintegrations per minute (DPM) per well. Data were 
analysed using a one-way ANOVA, *** p<0.001 (n=6). 
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5.4 Discussion 
Plant polyphenols act to both increase and decrease basal and insulin 
stimulated glucose uptake, but their concentrations, optimum incubation times 
and potential modes of actions vary (detailed in Section 1.6). This study shows 
that neither epicatechin nor EGCG, at the times and concentrations 
investigated, altered basal or insulin mediated glucose uptake in mature 3 T3-
L I adipocytes. 
Kaempferol and quercetin, both of which have similar structures to epicatechin 
(see Figure 5.4) both significantly improved insulin-mediated glucose uptake in 
mature 3T3-LI adipocytes when added for 3 days following differentiation 
(Fang et al. 2008). 5 and 10 /-lM of each compound had no effect, 20 /-lM of 
each increased glucose uptake by approximately 25% and 50 /-lM by 
approximately 300/0. It is possible that had epicatechin and EGCG been added 
at 50 /-lM for 3 days there may have been an increase in glucose uptake. The 
concentrations and treatment periods in this study were chosen based on the 
hypothesis that any effect may be downstream of ERK1I2. Furthermore, the 
concentrations of the flavonols used in the study by Fang et al are far too high 
to be achieved physiologically. As stated previously from studies on the 
EGCG content of green tea and pharmacokinetic data on EGCG in humans, 
attainment of such high levels are unrealistic. 
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Figure 5.4 Chemical structures of catechin (a), epicatechin (b), kaempferol (c) 
and quercetin (d). 
The basal conditions of the 3T3-Ll adipocytes used in the kaempferol and 
quercetin study vary significantly from those of the 3T3-Ll adipocytes used in 
this study. The differentiation protocol used by Fang et al. involves 48 h with 
1.72 ~ M M insulin, 1 ~ M M dexamethasone and 0.5 mM IBMX in DMEM (10% 
FCS and supplements) and maintenance for a further 7 days with 1.72 ~ M M
insulin in DMEM (10% FCS and supplements). Treatment for 3 days is also 
carried out in this medium. The present differentiation protocol involved 166 
nM insulin, 0.25 ~ M M dexamethasone and 0.5 mM IBMX for 48 hand 166 nM 
insulin for a further 48 h, after which, cells were maintained in insulin free 
medium (DMEM, 10% FCS and supplements) for a further 48 h before 
replacing it with a lower glucose DMEM (12.5 mM). EpicatechinlEGCG 
treatment was carried out in this lower glucose, insulin-free medium. This 
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difference in conditions may be a factor which could explain the difference in 
the way mature 3T3-L1 adipocytes behave when treated with very similar 
compounds. It may also be possible that the cells used by Fang et al. were 
insulin resistant, having been exposed to such a high concentration of insulin 
for a 12 day period, encompassing differentiation, maintenance and treatment. 
This study by Fang et al suggests that kaempferol and quercetin are acting as 
weak partial agonists for PP ARy and compete for the same binding site as a 
traditional PP ARy agonist, rosiglitazone. 
The effect of berberine, an isoquinoline alkaloid isolated from Chinese 
medicinal herbs such as Coptidis rhizoma and Cortex phellodendri has been 
studied in normal and insulin resistant 3T3-L1 adipocytes (Kim et al. 2007). 
Cells were made insulin resistant by exposure to 10 nM insulin for 12 h. This 
concentration is in fact 11170 of the concentration used during the 
differentiation and treatment in the study by Fang et al. The study by Kim et 
al. showed that 5 JlM berberine for 6 h significantly enhanced basal glucose 
uptake in normal and insulin resistant cells and modestly increased insulin-
stimulated glucose uptake. Interestingly, this same berberine treatment 
increased ERK1I2 phosphorylation, and the exposure to an ERK inhibitor 
PD98059, significantly decreased berberine stimulated glucose uptake. Further 
work in this paper went on to show that berberine mediated glucose uptake was 
a result of enhanced GLUT 1 expression, as a consequence of ERKl/2 
stimulation. 
There is further evidence to suggest that ERK1I2 plays a role in glucose 
transport (Harmon et al. 2004). Treatment of mature 3T3-Ll adipocytes with 
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the MEK inhibitors PD98059 and UO 126 inhibited insulin mediated glucose 
uptake. As both epicatechin and EGCG had increased ERK 112 
phosphorylation at 10 JlM and 0.1 JlM respectively, increased glucose uptake 
was expected. 
(-)Catechin, which is also structurally very similar to epicatechin (see Figure 
5.4), increased insulin dependent glucose uptake in differentiated 3T3-Ll 
adipocytes (Cho et al. 2007). Fully differentiated 3T3-Ll adipocytes were 
treated with 50 JlM (-) catechin for 24 h. Initially, the effect of ( -) catechin and 
various other flavonoids, including epicatechin, EGCG, quercetin, kaempferol 
and other structurally related compounds on adiponectin release, was 
investigated. ( -) Catechin increased adiponectin release to 213 % 0 f the control, 
interestingly; however, quercetin and kaempferol at 50 JlM suppressed 
adiponectin release to 54% and 420/0 of the control, respectively, whereas 
epicatechin and EGCG had no effect on adiponectin release. The effect of (-)-
catechin on adiponectin release was thought to be mediated by Kruppel-like 
factor 7, a transcription factor, the activity of which is linked to the expression 
of adiponectin, leptin, PP ARy, CIEBPu and aP2 (Cho et al. 2007). 
Genistein, an isoflavone derivative, inhibited both basal and insulin stimulated 
glucose uptake after15 min at 50 JlM (Bazuine et al. 2005). This is thought to 
be a result of interference with the insulin-induced glucose uptake directly and 
not by inhibiting GLUT4 translocation. Myricetin and quercetin, which are 
both structurally similar to epicatechin (see Figure 5.4), and catechin-gallate, 
when incubated with isolated rat adipocytes at 0.1-100 JlM also dose-
dependently decreased basal and insulin stimulated methylglucose uptake 
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(Strobel et al. 2005). As this study was carried out in isolated rat adipocytes as 
opposed to mature 3 T3-L 1 adipocytes, it may not be correct to compare this to 
the other studies. 
As compounds that are structurally related to epicatechin increase glucose 
uptake, it was hypothesized that epicatechin, if not EGCG would have the same 
result. The mechanisms of action appear to vary between the compounds and 
therefore it is difficult to predict how another compound may behave. It is 
possible that at 10 ).lM insulin, the glucose uptake was at the maximum 
response. The use of insulin at concentrations lower than 10 ).lM may have 
allowed the epicatechin or EGCG to further increase the glucose uptake 
response. 
There is evidence to suggest that EGCG is insulinomimetic and has been seen 
to lower glucose production in H4IIE rat hepatoma cells (Waltner-Law et al. 
2002). In this same study, it was reported that EGCG decreases expression of 
genes that control gluconeogenesis such as PEPCK and G6Pase and activates 
the same kinases as insulin and promotes phosphorylation of insulin signalling 
proteins such as IRS-1 and I R - ~ ~ in H4IIE cells (Waltner-Law et al. 2002). The 
in vivo evidence is somewhat contradictory as green tea, when given to rats as 
a replacement for drinking water for 3 weeks significantly reduced glucose 
uptake, accompanied by a decrease in translocation of GLUT4 (Ashida et al. 
2004). However after 12 weeks green tea significantly increased both basal 
and insulin mediated glucose uptake (Wu et al. 2004). 
Taking into consideration the studies by Fang et aI, Kim et al and Cho et al it 
appears that the majority of flavanols investigated to date increase glucose 
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uptake in 3 T3-L 1 adipocytes. This is through varymg mechanisms, one 
suggests partial agonism ofPP ARy and decreased adiponectin release, another 
through the ERKl/2 pathway, and the last through increased adiponectin 
release mediated by the suppression of Kruppel-like factor 7 (KLF7) protein. 
Evidence from in vivo studies using green tea is not consistent. Although in 
this study it is not evident that glucose uptake is altered by epicatechin or 
EGCG treatment, it is possible to suggest that under different conditions of 
concentration and time, epicatechin and EGCG could increase basal and/or 
insulin-mediated glucose uptake. 
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Gene Expression: 
effect of flavanols on F ABP4, leptin, 
resistin, adiponectin, adipsin, SREBP, 
PEPCK and PP ARy2 expression 
---- ------------------------- ~ - - - - - - -
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6 Gene Expression 
6.1 Introduction 
In order to try and understand the downstream effects offlavanol stimulation of 
3T3-Ll adipocytes, the expression of various genes, known to be either up or 
downregulated in obesity, was investigated. These genes were adipocyte fatty 
acid binding protein (F ABP4, also known as aP2), leptin, resistin, adiponectin, 
adipsinlcomplement factor D, sterol regulatory element binding protein 
(SREBP) and PP ARy2. See Table 6.1 below for whether these genes are up or 
downregulated in obesity, the fold change, if published, and whether there is 
evidence of their regulation by flavanols. In addition to these genes, 
expression of ~ - a c t i n n and eukaryotic 18S rRNA were measured as non-variant 
control genes. 
6.2 Methods 
3T3-Ll adipocytes were grown and differentiated as detailed in Chapter 2. 
When cells were fully differentiated they were treated with DMSO, 10 JlM 
epicatechin or 0.1 JlM EGCG for 6 or 24 hours. Cells were collected in 
TriReagent, and processed as detailed in Section 2.6. Details of primers, 
probes and TaqMan cycles are described in Section 2.6. Gene expression 
quantities (in arbitrary units) were determined from the mean of triplicate 
determinants of each sample. As stated in Section 2.6.7, data from Taqman 
was only used if the slope of the standard curve for each plate was between-
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3.2 and -3.6, indicating that the efficiency 0 f the process is almost 100%, In 
addition, Ct values of triplicate readings for an individual sample that were 
more than 0.5 Ct apart were excluded. Target gene expression was normalised 
by dividing the amount of target gene by the amount of reference gene for each 
sample. 
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Table 6.1 Genes measured by TaqMan analysis of 3T3-L1 adipocytes treated 
with 10 JiM epicatechin or 0.1 JiM EGCG for 6 and 24 h. 
References are (1) (Xu et al. 2006), (2) (Nadler et at. 2000), (3) (Ii et at. 
2002), (4) (Haluzik et al. 2004), (5) (Kao et at. 2000), (6) (Liu et at. 2006), (7) 
(Nagao et al. 2009), (8) (Ashida et al. 2004). 
Regulation of Gene Expression 
Gene 
In Obesity Flavanol Treatment 
FABP4 Marked increase (1) -
Leptin 3-fold increase (2) Decrease (5) 
Resistin 2.2-fold increase (3) Decrease (6) 
Adiponectin 3-fold decrease (4) Increase (7) 
Adipsin 8.3-fold decrease (2) -
SREBP 2.7-fold decrease (2) -
PEPCK 5.3-fold decrease (2) -
PPARy2 Decrease (2) Decrease (8) 
6.3 Results 
6.3.1 Variation Between Housekeeping Genes 
I8S RNA and ~ - a c t i n n were used as non-variant control or reference genes. 
Expression of the target genes was then normalised to expression of a reference 
gene. Expression of these two genes was not constant, and therefore was 
compared to decide which should be used as the reference gene. 
Figure 6.1 shows regression analysis of I8S and ~ - a c t i n n expression in the 
samples used. It is apparent that expression of these genes does not correlate, 
and this is further confIrmed by the very poor R2 value of 0.003. 
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Figure 6.1 Correlation between gene expression of 18S rRNA and fJ-actin in 
samples used for TaqMan. 
Results were analysed using Pearson's correlation. Measured in arbitrary 
units (au). 
Despite considerable variation of 18S rRNA expreSSIOn between treatment 
groups (Figure 6.2 (a)), compared to the slightly more consistent ~ - a c t i n n gene 
expression (Figure 6.2 (b)), a one-way ANOVA of 18S rRNA expression does 
not show any significant differences between the treatment groups. 
IiIilI DMSO 
~ E p i i
E3 EGCG 
(, h 24 h 
(a) Treatmenl' llmc (b) Treat menf Time 
Figure 6.2 Variation in 18S rRNA (a) and fJ-actin (b) expreSSlOn between 
treatment groups, measured in arbitrary units (au) . 
Comparisons of the data spread (see Table 6.2), calculated by dividing the 
range by the median of each treatment group, reveals that expression of 18S 
rRNA in these samples is more widely spread than that of ~ - a c t i i . . There is 
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almost a 5-fold difference between the lowest and highest value for 
median/range for I8S rRNA compared to only a 2 fold difference between the 
highest and lowest values for ~ - a c t i n . . Use of I8S rRNA as a reference gene for 
these samples would increase the variability between data, and for this reason, 
~ - a c t i n n was used as the reference gene. 
Table 6.2 Comparison of the spread of 18S rRNA and f3-actin gene expression 
in samples used for TaqMan analysis. 
Calculated by dividing the range by the median for each treatment group. 
Reference Treatment Mean SD Median Range Rangel 
Gene Quantity Median 
18S rRNA 6hDMSO 0.0127 0.0087 0.0102 0.0234 2.3054 
6 hEpi 0.0165 0.0054 0.0158 0.0120 0.7595 
6 hEGCG 0.0137 0.0064 0.0132 0.0152 1.1515 
24 hDMSO 0.0101 0.0017 0.0101 0.0047 0.4677 
24 h Epi 0.0071 0.0026 0.0078 0.0063 0.8129 
24hEGCG 0.0101 0.0036 0.0093 0.0081 0.8710 
~ - a c t i n n 6hDMSO 0.0600 0.0183 0.0544 0.0515 0.9467 
6 hEpi 0.0595 0.0155 0.0607 0.0465 0.7661 
6hEGCG 0.0499 0.0121 0.0496 0.0309 0.6236 
24hDMSO 0.0626 0.0257 0.0536 0.0700 1.3072 
24 h Epi 0.0548 0.0157 0.0539 0.0419 0.7781 
24hEGCG 0.0507 0.0116 0.0472 0.0295 0.6250 
6.3.2 Expression of Target Genes in Samples 
Data for expression of adipsin, SREBP, FABP4, PEPCK adiponectin and 
PPARy2 mRNA normalised to ~ - a c t i n n expression are shown in Table 6.3 and 
Figure 6.3. Levels of leptin and resistin mRNA in these samples were 
undetectable, and therefore data is not shown for these genes. 
Treatment of3T3-Ll adipocytes with 10 IlM epicatechin or 0.1 IlM EGCG for 
6 and 24 hours does not appear to significantly alter any of the genes 
investigated. 
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Table 6.3 Amount of target genes adipsin, SREBP, FABP4, PEPCK, 
adiponectin and PPARy2 mRNA, normalised to fJ-actin gene expression. 
Levels of leptin and resistin, although measured, were undetectable. (-) 
represents missing values. Gene expression was measured in arbitrary units 
(au). 
Sample Adipsin SREBP FABP4 PEPCK Adiponectin PPARr 
6hDMSO 1 0.8205 0.6219 0.8076 0.9086 0.3592 0.4270 
2 0.9055 0.8322 0.9656 0.9267 0.7244 0.5164 
3 0.8506 0.8858 0.8156 0.7365 0.3517 0.2900 
4 1.0450 0.7922 0.9255 0.7084 0.3122 0.4406 
5 0.8518 0.6636 0.7168 0.7547 0.2710 0.3648 
6 0.7962 0.7166 0.8102 0.6672 0.3696 0.3409 
6 hEpi 1 0.7475 0.7664 0.7213 0.7849 0.2983 0.3927 
2 0.8120 0.8388 0.7522 0.6984 0.2202 0.2475 
3 1.0456 1.0138 0.8840 0.8217 0.3491 0.5153 
4 0.8312 0.8489 0.8529 0.7262 0.2168 0.2650 
5 1.0065 0.6884 0.6483 0.6048 0.2156 0.2018 
6 0.7756 0.5710 0.8290 0.4859 0.3404 0.2527 
6hEGCG 1 0.8368 0.7189 0.7808 0.6554 0.2219 0.3075 
2 0.8704 0.9840 0.9013 0.8402 0.4571 0.3553 
3 0.8907 0.8058 0.7071 0.6917 0.2334 0.3275 
4 1.2130 1.0999 0.9169 0.7073 0.2211 0.2016 
5 0.6812 0.5860 0.7405 0.5914 0.2858 0.1722 
6 0.8521 0.7776 0.8300 0.6329 0.4472 0.2315 
24hDMSO 1 1.0326 1.0240 0.7480 0.9637 0.4470 0.5297 
2 0.9390 0.8934 0.6628 0.8687 0.2249 0.2377 
3 1.0422 0.8594 0.6860 0.7771 0.2931 0.3365 
4 1.2908 0.8009 0.8372 0.9792 0.2826 0.3395 
5 0.7499 0.7054 0.5426 0.6519 0.2989 0.2631 
6 0.9178 0.6966 0.6778 0.7506 0.2658 0.2669 
24 hEpi 1 1.1264 0.8739 0.7419 1.0110 0.2784 0.4458 
2 0.9068 0.8695 0.7091 0.7667 0.3975 0.5070 
3 0.6588 0.6524 0.3689 0.6111 0.2023 0.2351 
4 0.8253 0.7691 0.6144 0.7139 0.2167 0.3257 
5 0.6970 0.6419 0.6929 0.6610 0.3064 0.3533 
6 0.7207 0.6853 0.8695 0.7677 0.3120 0.2505 
24hEGCG 1 0.9103 0.8354 0.6109 0.8786 0.2482 0.2831 
2 0.9656 0.9856 1.0016 1.0895 (-) (-) 
3 0.7936 0.7247 0.6763 0.8033 0.3157 0.3962 
4 1.1482 0.8041 0.7537 0.8704 0.2417 0.2658 
5 0.8394 0.6577 0.7630 0.8443 0.3607 0.5110 
6 0.7390 0.6182 0.6604 0.7617 0.2837 0.2186 
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Figure 6.3 Expression of adipsin (a), SREBP (b) , FABP4 (c) , PEPCK (c), 
adiponectin (e) and PPARy (e) relative to fJ-actin. 
Leptin and res is tin levels were undetectable in these samples. Gene expression 
was measured in arbitrary units (au). 
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6.3.3 Correlation of Target Gene Expression 
As PP ARy and adiponectin are SREBP controlled genes, and F ABP4, PEPCK 
and adiponectin are all PPARy controlled, analysis of PP ARy or adiponectin 
expression compared to SREBP, and F ABP4, PEPCK or adiponectin 
expression compared to PP ARy should show some correlation (see Figure 6.4 
and Figure 6.5). 
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Figure 6.4 Correlation between gene expression of SREBP and PPARy (a) and 
adiponectin (b) relative to fJ-actin. 
Results were analysed using Pearson's correlation. Measured in arbitrary 
units (au). 
The poor R2 values of 0.078 for SREBP vs PP ARy (Figure 6.4 (a)), 0.024 for 
SREBP vs adiponectin (Figure 6.5 (b)) and 0.082 for PP ARy vs F ABP4 
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(Figure 6.5 (a)) shows that there is no correlation. However, the R:: values of 
0.330 for PPARy vs PEPCK (Figure 6.5 (b)) and 0.320 for PPARy vs 
adiponectin (Figure 6.5 (c)) show significant correlation as analysis by 
Pearson's correlation gives p values of 0.0003 and 0.0004 respectively. 
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Figure 6.5 Correlation between gene expression of PPARy and FABP4 (a), 
PEPCK (b) and adiponectin (c) relative to fJ-actin. 
Results were analysed using Pearson's correlation. Expression was measured 
in arbitrary units (au). 
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6.4 Discussion 
The aim of this chapter was to investigate the downstream effects of flavanol 
stimulation in 3 T3-L 1 adipocytes. Previous chapters have shown that both 
epicatechin and EGCG were able to alter adipokine release from 3T3-L 1 
adipocytes and stimulate ERK1I2 phosphorylation, but did not alter basal or 
insulin mediated glucose uptake. 
Time points for epicatechin and EGCG treatment were chosen on the basis that 
ERKI/2 phosphorylation was observed at 30 minutes. 6 hours was considered 
to be enough time for gene expression to alter, and 24 hours would show 
whether any change seen was long lasting. It is possible that neither of these 
time points were long enough to see changes in gene expression. 
Concentrations of 10 JlM for epicatechin and 0.1 IlM for EGCG were chosen 
on the basis that these produced the maximum ERK1I2 phosphorylation seen in 
Chapter 4. 
The use of eukaryotic I8S ribosomal RNA as a reference gene was 
unsuccessful and showed considerable variation between treatment groups, 
although this was not significant. ~ - a c t i n n expression was a lot more consistent 
in these samples, and was therefore used as the reference gene to which all 
target gene expression data was normalised. Studies carried out by others use 
both ~ - a c t i n n and eukaryotic I8S rRNA as reference genes but variability 
between samples and treatments is not commented on. It is possible that 
neither I8S rRNA or ~ - a c t i n n are appropriate reference genes for 3T3-LI cells. 
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Figure 6.6 Regulation of target genes by ERK112, CIEBPa., CIEBPfJ and 
PPARy. 
Adipogenesis is regulated by PPARy and CIEBPa. (Rosen et al. 2000), and the 
expression of these transcription factors is regulated by CIEBPfJ, which is 
phosphorylated by ERK112 during adipogenesis (Park et al. 2004). 
Phosphorylation of PPARy by ERK112 inhibits its activity (Hu et al. 1996). 
PPARy directly regulates the adipogenic genes F ABP41aP2 (Spiegelman et al. 
1993) and PEPCK (Tontonoz et al. 1995), and indirectly regulates the 
expression of adiponectin through activation of CIEBPa.. ADD11SREBP1c 
regulates the expression of PPARy by controlling the production of endogenous 
PPARy ligands (Kim et al. 1998) and directly activating transcription of 
PPARy (Fajas et al. 1999). In differentiated adipocytes, ADD11SREBP1c 
regulates adiponectin expression (Seo et al. 2004), transactivates leptin gene 
expression (Kim et al. 1998) and along with CIEBPa., regulates resistin gene 
expression (Seo et al. 2003). Leptin expression is also regulated by both 
CIEBPa., which activates it, and PPARy, which down-regulates it (Hollenberg 
et al. 1997). No connection has currently been elucidated between adipsin 
expression and any of the genes or transcription factors mentioned although its 
expression is sharply down-regulated in obesity (Nadler et al. 2000). 
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The genes investigated in this chapter; F ABP4/aP2, leptin, resistin, 
adiponectin, adipsin, ADDlISREBPlc, PEPCK and PPARy2, were all chosen 
on the basis that they were up or down-regulated in obesity. Their regulation is 
in some way connected to the ERK1I2 pathway and they have complex 
interrelationships with each other (summarised in Figure 6.6). 
In this study, no significant changes in expression of these genes were 
observed following treatment with 10 J.lM epicatechin or 0.1 J.lM EGCG for 6 
or 24 hours. Although some of these genes are up-regulated in obesity, and 
others down-regulated (see Table 6.1), they are all upregulated during 
adipogenesis (Fajas et al. 1998; Nadler et al. 2000; Rosen and Spiegelman 
2000; Walczak and Tontonoz 2002). As the 3T3-LI adipocytes used for this 
study were fully differentiated, adipogenesis is considered to be complete, and 
the genes involved in it may no longer be upregulated. 
Figure 6.6 shows how the target genes investigated in this study are regulated. 
Resistin and leptin expression are controlled by C/EBPa, which, through 
C / E B P ~ ~ is activated downstream ofERK1I2. As both epicatechin and EGCG 
were shown to phosphorylate ERK1I2 (Chapter 4), it might be expected that 
they would increase the expression of resistin and leptin. Levels of leptin and 
resistin were undetectable in any of the samples tested, and perhaps, although 
the genes are expressed, their levels are far too low to be detected by this 
method. Detection of resist in (Patel et al. 2003) and leptin (Schoof et al. 2004) 
by TaqMan is reported in the literature, but only in human tissue and not in 
3T3-LI cells. Leptin expression is also negatively regulated by PPARy, 
however there is evidence to suggest that PP ARy activity is inhibited by 
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phosphorylation by activated ERK1I2 (Hu et al. 1996; Adams et al. 1997: 
Camp and Tafuri 1997; Reginato et al. 1998; Chan et al. 2001). This should 
mean, therefore, that PP ARy should be unable to inhibit leptin expression, 
providing further rationale for the expected increase in leptin expression. 
PP ARy also regulates the expression of adiponectin, F ABP4 and PEPCK, 
genes which are down-regulated in obesity but up-regulated during 
adipogenesis. As previously mentioned, phosphorylation of PP ARy by 
ERK1I2 inhibits its activity (Hu et al. 1996; Adams et al. 1997; Camp and 
Tafuri 1997; Reginato et al. 1998; Chan et al. 2001), and therefore activation 
of ERK1I2 by epicatechin and EGCG should decrease expression of these 
genes. 
ADDliSREBP1c opposes the action of ERK1I2 by activating PPARy, so 
indirectly activating expression of PEPCK and F ABP4/aP2. Additionally, 
ADDliSREBP1c directly up-regulates leptin, resistin and adiponectin. There 
is also some evidence to suggest that ERK1I2 may regulate the expression of 
SREBP1c in skeletal muscle (Boonsong et al. 2007). 
F ABP4, PEPCK and adiponectin are regulated by PP ARy and have PP AR 
response elements (PPREs), and ADDliSREBP1c regulates PPARy, 
adiponectin, leptin and resistin. It therefore follows that expression of these 
pairs of genes should correlate. This however was not the case for PP ARy and 
FABP4/aP2, ADDliSREBP1c and PPARy or ADDliSREBP1c. However 
there did appear to be correlation between expression of PP ARy and PEPCK 
and PP ARy and adiponectin. As there were no significant changes in 
expression of these genes, it is somewhat unexpected that expression of only 
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two pairs of these genes should correlate, whereas the other pairs did not show 
significant correlation, especially as F ABP4 and PEPCK show very similar 
patterns of expression in these samples. However, as there are no changes in 
gene expression, it is possible that this is just the normal range of distribution 
of gene expression in these samples and therefore there is not suffiecient 
variation to detect any correlation. 
The majority of gene expression work that has been reported in the literature is 
the result of analysis of adipose tissue from animal models of obesity. This 
could mean that any changes could be caused by whole body metabolic effects 
that are not present in cell culture models. Another explanation is that the 
changes reported in these instances are the result of altered gene expression in 
a latent preadipocyte population, whereas this study used the 3T3-Ll adipocyte 
cell model and efficient differentiation of preadipocytes to adipocytes was 
ensured before cell culture dishes were selected for treatment. 
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7 Discussion 
Green tea consumption has been believed for centuries to have sio-nificant e 
health benefits. More recently, the effects of green tea, and more importantly, 
the flavanols that are its active constituents, have been investigated with 
regards to their effects on obesity. Intraperitoneal injection and feeding studies 
in rodents and feeding studies in humans, demonstrate that green tea flavanols, 
and more specifically EGCG, are able to prevent increases in body weight and 
adipose tissue mass when both lean and obese subjects are fed a high fat diet. 
Additionally, other factors such as decreased leptin levels and lipogenesis and 
increased adiponectin levels and ~ - o x i d a t i o n , , suggest that EGCG and related 
flavanols are able to beneficially modulate the development of obesity. 
The aim of these studies was to investigate the effect of green tea derived 
catechins upon adipocyte metabolism. The first objective was, therefore, to 
establish an efficient cell culture system in which adiponectin and resistin 
could be measured by ELISA. Further to this, the effects of (+ )-catechin, (-)-
epicatechin and (-)-EGCG on adiponectin release were measured. Under high 
medium glucose concentrations, catechin and epicatechin appear to positively 
regulate adiponectin and resistin release, whereas EGCG negatively regulates 
this. The EGCG effect on adiponectin release is dependent on medium glucose 
concentration - lowering the medium glucose concentration from 25 to 12.5 
mM ablated the lowering effect that EGCG had on adiponectin release. 
Interestingly, medium glucose concentration did not affect the extent of the 
EGCG-induced decrease in resistin release. Resistin levels are increased in 
obesity and associated insulin resistance, and the effect of EGCG in lowering 
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resistin levels without lowering adiponectin levels (under lower, more 
physiological glucose concentrations) can be paralleled to the action of TZDs, 
which decrease resistin expression through PP ARy and subsequently improve 
insulin resistance (Hartman et al. 2002). 
Studies in the literature investigating adipokine release as a result of flavonoid 
treatment demonstrate that adipokine release is flavonoid specific. A study by 
Cho et al demonstrated that 50 JlM catechin, epicatechin 3-gallate, quercetin 
and kaempferol for 24 haltered adiponectin release from 3T3-Ll adipocytes to 
200%, 79%, 54% and 42% respectively of the control. In this study, EGCG 
and epicatechin had no effect on adiponectin release (Cho et al. 2007). 
Feeding studies, on the other hand, provide evidence that EGCG can increase 
circulating levels of adiponectin (Potenza et al. 2007; Shimada et al. 2007). 
The [mdings of this thesis are not in agreement with many of the studies cited; 
many studies in the literature have used primary cell or in vivo models, so it is 
very difficult to draw comparisons. In addition, the studies that have used the 
3T3-Ll adipocyte model all use varying differentiation and maintenance 
conditions, which in some cases, may have resulted in the adipocytes becoming 
insulin resistant. 
In order to try and understand the mechanisms by which the flavanols were 
able to alter adipokine release, the ERK1I2 MAPK signalling pathway was 
investigated. Epicatechin and EGCG both increased ERKl/2 phosphorylation 
in the 3T3-Ll system, although there was a lOO-fold difference in optimum 
concentrations to produce the same significant effect. Evidence in the 
literature suggests that gallated catechins, especially EGCG, are more active 
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than other catechins as the gallyl and galloyl groups have conformational 
flexibility (Hung et al. 2005). This may be important for interactions with 
other molecules and may allow EGCG to bind with a receptor. EGCG also 
contains the largest number of hydroxyl groups on its three aromatic rings, and 
these may be important for hydrogen bonding. Having established the 
stimulatory effect of epicatechin and EGCG on the ERK1I2 pathway, upstream 
activation by way of GTPyS binding was measured. EGCG was the most 
potent in the GTPyS binding assay and negatively regulated this process. 
Although cAMP generation was investigated as another mechanism 0 f 
upstream activation, a functional readout could not be obtained due to technical 
problems with the assay normally used for this purpose. 
A study by Fujishiro et al showed that chronic activation ofERK1I2 in 3T3-Ll 
adipocytes leads to up-regulation of GLUTl expression and down-regulation 
of GLUT4 expression, resulting in slightly increased basal glucose transport 
but decreased insulin-stimulated transport (Fujishiro et al. 2003). However, in 
a study by Harmon et al in which mature 3T3-Ll adipocytes were treated with 
the MEK inhibitors PD98059 and UOl26, insulin-mediated glucose uptake was 
inhibited (Harmon et at. 2004). Therefore, glucose uptake was chosen as a 
potential physiological outcome downstream of ERK1I2 phosphorylation; 
however neither epicatechin nor EGCG were able to alter this. There is plenty 
of evidence to suggest that other flavonoids are able to alter glucose uptake, 
kaempferoI, quercetin (Fang et al. 2008) and (-) catechin (Cho et al. 2007) 
significantly improve insulin-mediated glucose uptake in 3T3-Ll adipocytes, 
and berberine enhances basal glucose uptake (Kim et al. 2007). Genistein 
(Bazuine et at. 2005), myricetin, quercetin and catechin-gallate (Strobel et al. 
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2005) however, inhibit both basal and insulin-stimulated glucose uptake. The 
majority of these studies have been carried out in 3T3-Ll adipocytes so should 
be comparable to the results in this study, however in some cases the basal 
conditions of the 3T3-Ll adipocytes vary significantly to those in this study. 
Notably the continued high insulin levels in the study by Fang et al may have 
resulted in the 3T3-Ll adipocytes becoming insulin resistant. It is possible that 
under different time and concentration conditions, epicatechin and EGCG may 
be able to modify basal or insulin-stimulated glucose uptake. 
The fmal investigation into the effects of flavanols was to explore the 
expression of various genes known to be altered as a result of obesity (Nadler 
et al. 2000; Li et al. 2002; Haluzik et al. 2004; Xu et al. 2006). These genes 
are also up-regulated during adipogenesis (Fajas et al. 1998; Nadler et al. 2000; 
Rosen and Spiegelman 2000; Walczak and Tontonoz 2002). The expression of 
the genes chosen is under complex regulation by the ERK1I2 pathway, the 
C/EBP transcription factors and PP ARy throughout adipogenesis. As the 3T3-
L 1 adipocytes used for this study were fully differentiated, adipogenesis is 
considered to be complete, and the genes involved in it may no longer be up-
regulated. Although significant changes in expression of these genes were not 
determined as a result of epicatechin or EGCG treatment, there appeared to be 
some correlation between some pairs of genes where one regulates the other. 
There is some evidence in the literature indicating that adipocyte gene 
expression is altered as a result of flavonoid treatment (Kao et al. 2000; Ashida 
et al. 2004; Liu et al. 2006; Nagao et al. 2009), however these are mostly in 
animal models, or also may be the result of changes in preadipocytes as 
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compared to mature adipocytes. Genes were chosen for investigation in this 
study on the basis of results from animal models, however, it is difficult to 
compare these studies to those carried out in animal or human models, or to 
extrapolate any fmdings to these models as the system used in these studies is 
an immortalised cell line, comprising only one cell type. In whole body 
models, compounds such as the flavanols are not able to target one cell type; 
they affect the whole body and can have direct and indirect effects on many 
tissues, which may then result in paracrine effects to other tissues in the body. 
Furthermore, in whole body systems, metabolism and bioavailability of these 
compounds is an issue, whereas this is not the case in the 3T3-Ll model used 
in these studies. As previously stated, evidence from pharmacokinetic data in 
humans suggests that attainment of high levels of EGCG in the body is 
unrealistic. It is therefore difficult to transfer data in immortalised cell lines or 
isolated primary cells to a whole body system in which such low plasma levels 
are achievable. 
Further work that may help to understand the effects and mechanisms, if any, 
would firstly involve obtaining a functional readout of the cyclic AMP 
generation assay, in order to further elucidate how signalling upstream of the 
ERK1I2 pathway is occurring. Secondly, transactivation ofPP ARy might yield 
interesting results, as although PP ARy gene expression was not altered as a 
result of flavanol treatment, there was correlation between the expression of 
PPARy and PEPCK and PPARy and adiponectin. Investigating all of the 
downstream ERK1I2 targets and the signalling pathways activated and genes 
regulated would help to ascertain what the downstream targets and 
physiological outcomes of the flavanol actions on ERK1I2 are. Only the 
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adipokines adiponectin and resistin were investigated as secreted factors from 
the 3T3-Ll adipocytes, but a more thorough investigation of all secreted 
factors may help to further determine the effects that flavanols have on 3T3-Ll 
adipocytes. This could be done both by a Luminex assay to measure known 
adipokines and cytokines, and by co-culture with other cell types to investigate 
the direct effect these potentially unknown secreted products may have on 
other cell types. 
A thorough investigation of adipokine release, ERK1I2 signalling, glucose 
uptake and gene expression, under the influence of flavano 1 treatment, showed 
that although molecular changes occurred in the 3T3-Ll adipocyte system, 
these did not translate into functional readouts. Therefore, it appears unlikely 
that these have major direct effects on adipocytes function. 
~ - - - - - ------------:-:-: 
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